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Background and Aims: Cells in pancreatic ductal adenocarcinoma (PDAC) undergo 89 
autophagy, but its effects vary with tumor stage and genetic factors. We investigated the 90 
consequences of varying levels of the autophagy related 5 (Atg5) protein on pancreatic 91 
tumor formation and progression.  92 
 93 
Methods: We generated mice that express oncogenic Kras in primary pancreatic cancer 94 
cells and have homozygous disruption of Atg5 (A5;Kras) or heterozygous disruption of Atg5 95 
(A5+/-;Kras), and compared them with mice with only oncogenic Kras (controls). Pancreata 96 
were analyzed by histology and immunohistochemistry. Primary tumor cells were isolated 97 
and used to perform transcriptome, metabolome, intracellular calcium, extracellular cathepsin 98 
activity, and cell migration and invasion analyses. The cells were injected into wildtype 99 
littermates, and orthotopic tumor growth and metastasis were monitored. Atg5 was knocked 100 
down in pancreatic cancer cell lines using small hairpin RNAs; cell migration and invasion 101 
were measured, and cells were injected into wildtype littermates. PDAC samples were 102 
obtained from independent cohorts of patients and protein levels were measured on 103 
immunoblot and immunohistochemistry; we tested the correlation of protein levels with 104 
metastasis and patient survival times. 105 
 106 
Results: A5+/-;Kras mice, with reduced Atg5 levels, developed more tumors and 107 
metastases, than control mice, whereas A5;Kras mice did not develop any tumors. Cultured 108 
A5+/-;Kras primary tumor cells were resistant to induction and inhibition of autophagy, had 109 
altered mitochondrial morphology, compromised mitochondrial function, changes in 110 
intracellular Ca2+ oscillations, and increased activity of extracellular cathepsin L and D. The 111 
tumors that formed in A5+/-;Kras mice contained greater numbers of type 2 macrophages 112 
than control mice, and primary A5+/-;Kras tumor cells had upregulated expression of 113 
cytokines that regulate macrophage chemoattraction and differentiation into M2 macrophage. 114 
Knockdown of Atg5 in pancreatic cancer cell lines increased their migratory and invasive 115 
capabilities, and formation of metastases following injection into mice. In human PDAC 116 
samples, lower levels of ATG5 associated with tumor metastasis and shorter survival time. 117 
 118 
Conclusions: In mice that express oncogenic Kras in pancreatic cells, heterozygous 119 
disruption of Atg5 and reduced protein levels promotes tumor development, whereas 120 
homozygous disruption of Atg5 blocks tumorigenesis. Therapeutic strategies to alter 121 
autophagy in PDAC should consider the effects of ATG5 levels to avoid the expansion of 122 
resistant and highly aggressive cells. 123 
 124 
Key words: Atg5-levels, pancreatic carcinogenesis, Ca2+, mitochondria, cathepsins 125 
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INTRODUCTION: 126 
 127 
Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, 128 
frequently exhibits mutations in the KRAS oncogene leading to constitutive activation of the 129 
KRAS-signaling pathway. Oncogenic KRAS has been shown to promote tumorigenesis 130 
through cell-autonomous (proliferation, migration, survival) and non-cell autonomous (tumor 131 
microenvironment) effects. In addition, it has also recently been associated with pro-132 
tumorigenic alterations in cell metabolism, protein synthesis, cell growth, and stimulation of 133 
autophagy 1. 134 
Autophagy is a central regulator of metabolism and cell homeostasis 2, 3. During baseline or 135 
cell stress/ nutrient starvation-triggered autophagy, cytoplasmic constituents are engulfed 136 
into double membrane autophagosomes and delivered to lysosomes for degradation and 137 
recycling. Autophagy typically orchestrates detoxification, release of nutrients, and 138 
restoration of cell homeostasis. Multiple autophagy genes (Atg) are involved in 139 
autophagosome formation. An important player is Atg5, which binds to Atg12-Atg16 and 140 
mediates conjugation of LC3 I to phosphatidylethanolamine (PE), forming LC3 II. LC3 II is 141 
attached to the autophagosomal membrane and interacts with multiple adaptor proteins (e.g., 142 
Sqstm1/ p62) shuttling cargo molecules to autophagosomes.  143 
Atg5 is required for formation of LC3 II-positive autophagosomes and maintenance of 144 
autophagic flux. Inhibition of autophagy by deletion of Atg5 in the context of oncogene 145 
activation/ tumor suppressor gene inhibition has been performed in multiple tissue types to 146 
study the role of autophagy during various stages of carcinogenesis 3. Surprisingly, Atg5-147 
deletion in the pancreas 4, 5 and lung 6 has been shown to increase tumor initiation but 148 
decrease tumor progression indicating a tumor stage-dependent action of autophagy. The 149 
underlying mechanisms of these phenotypes were proposed to be increased DNA-damage, 150 
cell stress, apoptosis, and metabolic deficiencies. 151 
Here we describe for the first time the opposing functions that varying levels of Atg5 have 152 
during pancreatic carcinogenesis. With the help of well-established models of in vitro and in 153 
vivo pancreatic carcinogenesis we show that stages of pancreatic carcinogenesis critically 154 
depend on the levels of Atg5. Complete loss of Atg5 in the pancreas during embryogenesis 155 
accelerates tumor initiation but blocks tumor progression, while monoallelic loss significantly 156 
increases tumor incidence and metastasis rate. Importantly, deletion of one Atg5-allele and 157 
reduction of Atg5 protein levels increases PDAC aggressiveness through cell-autonomous 158 
and non-cell autonomous effects, collectively enhancing tumor malignancy. ShRNA-159 
mediated knockdown of Atg5 further highlights that the exact association of Atg5-levels with 160 
PDAC phenotype follows a non-linear pattern. Thus, our results not only provide novel 161 
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evidence on the role of autophagy during PDAC development and progression but also 162 
highlight the importance of exercising caution when blocking autophagy in PDAC. 163 
 164 
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MATERIALS AND METHODS: 165 
 166 
All authors had access to the study data and reviewed and approved the final manuscript. 167 
 168 
Mice 169 
The Atg5flox/flox  7, Ptf1a-creex1 8, LSL-KrasG12D knock-in 9 strains were interbred to generate 170 
compound mutant Atg5flox/flox ; Ptf1a-creex1; LSL-KrasG12D (termed A5;Kras), Atg5flox/+;Ptf1a-171 
creex1; LSL-KrasG12D (termed A5+/-;Kras), and Ptf1a-creex1; LSL-KrasG12D (termed Kras) 172 
control animals. TG(CAG-EGFP/Map1lc3b)53Nmz transgenic mice (termed GFP-LC3) 10 173 
interbred with A5+/-;Kras mice to generate A5;Kras (termed GFP-LC3;A5;Kras),  A5+/-;Kras 174 
(termed GFP-LC3;A5+/-;Kras) or Kras (termed GFP-LC3;Kras) mice with concomitant GFP-175 
LC3 expression were used for autophagosome detection. Littermate animals without Ptf1a-176 
creex1 expression were used for orthotopic transplantation and tail vein injections. For all the 177 
experiments, mice were housed under specific pathogen-free conditions. All animal 178 
procedures were reviewed and approved by the Zentrum für Präklinische Forschung of the 179 
Technische Universität München, which follows the federal German guidelines for ethical 180 
animal treatment (Regierung von Oberbayern).  181 
 182 
Statistical Analysis 183 
Data are displayed as mean ± standard deviation (SD). Student t test was performed to 184 
compare the parameters for the groups by using GraphPad Prism. An appropriate and 185 
statistical significance was set at *P<0.05, **P<0.01, and ***P<0.001. Survival rates were 186 
calculated and displayed by the Kaplan–Meier method. Survival curves were compared by 187 
log-rank test using GraphPad Prism. 188 
 189 
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RESULTS: 190 
 191 
Monoallelic loss of Atg5 influences metastatic load 192 
Autophagy can be visualized in the pancreas as GFP-LC3 positive autophagosomes using 193 
GFP-LC3 transgenic mice (Figure 1A). Under normal fed conditions, GFP-LC3 puncta are 194 
visible in acinar cells. During pancreatic carcinogenesis, autophagosomes are detectable in 195 
pre-malignant acinar-to-ductal metaplasias (ADM), pancreatic intraepithelial neoplasias 196 
(PanIN), as well as in full-blown pancreatic tumors and metastasis (liver) of GFP-LC3;Kras 197 
mice. In addition, cells isolated from pancreatic tumors and their metastases are positive for 198 
GFP-LC3 autophagosomes (data not shown). Interestingly, PanIN-adjacent normal acinar 199 
cells lack GFP-LC3-positive puncta, despite harboring the oncogenic KrasG12D mutation 200 
(white star, Figure 1A). With complete loss of Atg5 however, only a diffuse staining is visible 201 
(Supplementary Figure 1A). Autophagy is therefore present in each stage of pancreatic 202 
tumor formation and metastasis.  203 
To elucidate the role of autophagy during PDAC, we generated mice with homozygous 204 
(A5;Kras) and heterozygous (A5+/-;Kras) deletion of Atg5 and compared them to autophagy 205 
proficient Kras mice. As previously shown 4, complete loss of Atg5 accelerates tumor 206 
initiation by significantly enhancing ADM (Supplementary Figure 1A, B, D) and increasing 207 
pancreas/body weight index at 4-weeks of age (Supplementary Figure 1C); however, 208 
A5;Kras mice only progress to PanIN-1 at 9-weeks of age (Supplementary Figure 1B, E) and 209 
do not develop more malignant stages of the disease (Supplementary Figure 1E). In fact 210 
A5;Kras mice have reduced survival (Supplementary Figure 1F) associated with severe 211 
pancreatic degeneration as shown by a significantly lower relative pancreatic weight starting 212 
at 18 weeks of age (Supplementary Figure 1C). A5+/-;Kras mice did not differ in ADM/ PanIN 213 
formation, pancreas/ body weight ratio or survival compared to Kras mice (Supplementary 214 
Figure 1B, C, D, E, F). Of note, pancreatitis responses and pancreatitis-associated 215 
progression of ADM/ PanIN-lesions were not different in all mouse lines (data not shown). 216 
Surprisingly however, monoallelic loss of Atg5 significantly increased tumor and metastasis 217 
incidence, determined at the time of sacrifice, compared to autophagy proficient and 218 
autophagy deficient genotypes (Figure 1B, C, D, Supplementary Table 1). As shown in 219 
Figure 1B, primary tumors formed in A5+/-;Kras mice were characterized by a high degree of 220 
histologic malignancy; at the same time multiple metastatic foci were visible in target tissues, 221 
a phenotype normally not present in autophagy proficient Kras mice. 222 
Therefore, monoallelic and not biallelic loss of Atg5 critically influences pancreatic tumor 223 
initiation, progression, and metastasis. 224 
 225 
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Autophagy is constitutively active after monoallelic loss of Atg5 influencing survival 226 
in vitro. 227 
To mechanistically examine the effect of monoallelic Atg5-loss on PDAC, we firstly evaluated 228 
how monoallelic Atg5-loss influences autophagy. As autophagic flux can be readily analyzed 229 
in vitro, we isolated primary pancreatic cancer cells from Kras and A5+/-;Kras mice. During 230 
our study, one A5;Kras mouse from all A5;Kras mice analyzed (n=24, Supplementary Figure 231 
1B) stochastically developed PDAC. This cell line could not be propagated in vitro (data not 232 
shown) and was used only as a control for Atg5 protein expression analysis. Figure 2A 233 
shows Atg5 protein expression, detected as a complex with Atg12, in the cell line lysates. 234 
Importantly, reduction in Atg5 protein was evident in A5+/-;Kras cells and in A5+/-;Kras mice 235 
(Figure 2A). Cell morphology and cell proliferation capacities were not influenced (Figure 236 
2B). Interestingly however, while autophagic flux was not different between Kras and A5+/-237 
;Kras in vitro and in vivo (Figure 2A, 2D), autophagy regulation after treatment with 238 
autophagy activators or inhibitors was influenced. Specifically, starvation with HBSS 239 
functionally affected Kras cells by significantly reducing colony numbers compared to 10% 240 
FCS-containing medium (Figure 2C). Colony formation in A5+/-;Kras cells was not 241 
compromised. FCS-starvation led to an accumulation of LC3-II, which was even more 242 
evident in Kras versus A5+/-;Kras cells after co-treatment with chloroquine (Figure 2D). 243 
Autophagic flux inhibition was validated by elevated p62 protein levels in both cell types, 244 
specifically however in Kras cells after co-treatment with chloroquine (Figure 2D). 245 
AMPKalpha phosphorylation was slightly increased in A5+/-;Kras cells, suggesting that 246 
AMPKalpha remains responsive to starvation in A5+/-;Kras cells (Figure 2D). In addition, 247 
increasing chloroquine treatment significantly affected colony formation only in Kras cells 248 
(Figure 2D). Finally, Cyto-ID-mediated quantification of autophagosomes after FCS-249 
starvation showed an elevation in autophagosome numbers only in Kras cells (Figure 2E). Of 250 
note, treatment of Kras and A5+/-;Kras cells with various metabolic regulators (10% FCS, 6-251 
AA, rotenone, galactose/ glutamine, high glucose) did not differentially affect the colony 252 
forming capacities of Kras and A5+/-Kras cells (Supplementary Figure 2A-E). 253 
Thus, monoallelic loss of Atg5 and reduced Atg5 protein levels lead to specific changes in 254 
autophagic regulation, making A5+/-;Kras cell lines more resistant to standard autophagy 255 
stimulation and inhibition.  256 
 257 
Monoallelic loss of Atg5 increases metastatic properties of cancer cells in vitro and in 258 
vivo. 259 
As A5+/-;Kras mice had a higher tumor and metastasis incidence we aimed to analyze in 260 
more detail the effect of Atg5-monoallelic loss on tumor and metastasis formation. In vitro 261 
experiments with Kras and A5+/-;Kras cells revealed significantly increased anoikis 262 
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resistance (Figure 3A), migration, invasion, and cell spreading in A5+/-;Kras cells (Figure 263 
3B), all of which influence metastatic capacities of tumor cells. Filopodia formation, an 264 
indicator of cell spreading, was also clearly detectable in A5+/-;Kras cells while Kras cells 265 
displayed only small protrusions (Figure 3B). Tumor formation after orthotopic transplantation 266 
was similar in Kras and A5+/-;Kras cell lines, with both cell lines forming CK19-positive ductal 267 
tumors, morphologically resembling primary tumors (Supplementary Figure 3A). However, 268 
metastasis incidence (%) after orthotopic transplantation was significantly increased in A5+/-269 
;Kras cells, with cells metastasizing to sites including lymph nodes, liver, lung, and spleen 270 
(Supplementary Figure 3B). In a second model for target tissue colonization, significantly 271 
more lung tumors (%) were formed after tail vein injection of wildtype mice with A5+/-;Kras 272 
versus Kras cells (Figure 3C). Body weight of mice, as an indicator of cachexia, was also 273 
reduced after injection with A5+/-;Kras cells (Supplementary Figure 3C). In addition to lung 274 
tumor formation, some mice exhibited liver and spleen metastasis, implying higher 275 
aggressiveness of pancreatic tumor cells after monoallelic loss of Atg5 (Supplementary 276 
Figure 3D). Proliferation of lung tumors (Figure 3C), as well as in vitro proliferation of A5+/-277 
;Kras cell lines after re-isolation from lung tumors (Supplementary Figure 3D), was also 278 
increased.  279 
To elucidate the association between Atg5 expression levels and PDAC-malignancy, we 280 
knocked down Atg5 in Kras cell lines using shRNAs with various knockdown efficiencies 281 
(54%, 58%, 81%, 86%, and 94%). All shRNAs were able to affect Atg5 expression levels 282 
with the aforementioned efficiency at the mRNA (data not shown) and protein level (Figure 283 
3D). As 58% Atg5 knock down resembles the situation after monoallelic loss of Atg5 we 284 
continued with these cells for further analyses. We also utilized 94% Atg5 knock down cells, 285 
to determine, whether the levels at which Atg5 influences PDAC phenotype coincide with a 286 
certain percentage. Importantly, knock down of Atg5 by 58% or 94% significantly enhanced 287 
migration and invasion in vitro (Figure 3E) as well as lung metastasis in vivo (Figure 3F). 288 
Colony formation after cultivation in 10% FCS-containing medium was not affected 289 
(Supplementary Figure 3E). 290 
Therefore, our data suggest that monoallelic loss of Atg5 during embryonic development as 291 
well as shRNA-mediated Atg5-dosage reduction increase metastatic capacities and 292 
aggressiveness of cells in vitro and in vivo. 293 
 294 
Monoallelic loss of Atg5 is sufficient to induce transcriptional and metabolic changes. 295 
Autophagy is known to regulate transcription 11. In addition, the autophagy-lysosomal 296 
pathway is controlled on a transcriptional level in PDAC 12. To investigate how monoallelic 297 
loss of Atg5 increases tumor cell metastasis and aggressiveness, we therefore performed 298 
transcriptomic analyses in Kras and A5+/-;Kras pancreatic tumor cells. Surprisingly, loss of 299 
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one allele of Atg5 was sufficient to change transcriptomic pathway regulation on a large 300 
scale. Gene enrichment analysis revealed that loss of one allele of Atg5 led to a reduction in 301 
the number of upregulated pathways by half (Figure 4A). Functional classification of the most 302 
significantly regulated genes (Supplementary Figure 4C) identified multiple cellular functions 303 
affected by monoallelic loss of Atg5 (Figure 4B). Most importantly, an increase was seen in 304 
metabolism, immunity, development, and vesicular trafficking/homeostasis associated 305 
cellular functions; a decrease was seen in adhesion and cell cycle associated cellular 306 
functions (Figure 4B). Classification of KEGG-pathways confirmed the increase in 307 
inflammation and the decrease in proliferation/ synthesis-associated pathways in A5+/-;Kras 308 
cells (Figure 4C, Supplementary Figure 4B). Interestingly, the gene set associated with 309 
lysosomal function was enriched in A5+/-;Kras cells (Figure 4C, Supplementary Figure 4B) 310 
further supporting a deregulation in vesicular homeostasis. Of note, gene enrichment 311 
analysis using the Transcription Factor Binding Motif database further supported the 312 
enrichment of development and inflammation-associated gene sets and the downregulation 313 
of proliferation-associated gene sets in A5+/-;Kras cells (Supplementary Figure 4A, 4B). 314 
Because autophagy influences metabolic pathways, we performed non-targeted metabolic 315 
profiling in Kras and A5+/-;Kras cell lines and their supernatants (Figure 4D). Importantly, 316 
A5+/-;Kras cells contained increased amounts of nucleotides and spermidine, representing 317 
deregulated proliferation, elevated amounts of oxidative and cell stress-associated 318 
metabolites (e.g., S-nitrosoglutathione, hypotaurine, S-lactoylglutathione, involved in 319 
oxidative stress, and ADP-ribose connected with cell stress), increased 3/2-320 
phosphoglycerate implicated in glucose metabolism, and changes in the amounts of fatty 321 
acids engaged in energy metabolism (e.g., myristoylcarnitine, valerylcarnitine). Supernatants 322 
of A5+/-;Kras cells showed changes in lysolipids (e.g., 1-Stearoyl-GPE) and other lipids (e.g., 323 
polyunsaturated fatty acids), indicative of changes in membrane composition/ signaling; 324 
arginine, suggesting an influence on the immune microenvironment (macrophages); and 6-325 
phosphogluconate, a metabolite associated with the pentose phosphate pathway. 326 
Thus, monoallelic loss of Atg5 is sufficient to induce global transcriptomic and metabolomic 327 
changes, mostly in pathways associated with metabolism, inflammation, and vesicle 328 
homeostasis. 329 
 330 
Monoallelic loss of Atg5 reduces mitochondrial functionality. 331 
To gain further insight into the effect of monoallelic Atg5-loss on metabolism, we performed a 332 
series of experiments related to mitochondrial functionality and cell stress. Electron 333 
microscopy revealed changes in mitochondrial morphology. In particular, there was an 334 
increase in mitochondrial fission and differences in cristae stacking between Kras and A5+/-335 
;Kras cells (Figure 5A). Protein expression analyses illustrated slight increases in oxidative 336 
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phosphorylation associated mitochondrial proteins (COX II/ IV, ATP Core 2), in mitochondrial 337 
stress-associated SOD2, and in endoplasmic reticulum (ER)-stress associated BiP 338 
(Supplementary Figure 5A). ER-stress was also indicated by an elevation in the spliced form 339 
of Xbp1 (Supplementary Figure 5A). Expression of p53 however was not influenced (data not 340 
shown). Mitochondrial function was further assessed by detailed comparison of oxidative and 341 
glycolytic capacities in Kras and A5+/-;Kras cell lines (Figure 5B-D). We detected a decrease 342 
in oxidative capacity, as evidenced by cellular respiration rate, mitochondrial respiration rate, 343 
and maximum substrate oxidation rate, at the expense of mitochondrial ATP production 344 
(Figure 5B). In addition A5+/-;Kras cells showed a reduction in glycolysis, as evidenced by 345 
decreased cellular acidification rates, maximum glycolytic capacity, and baseline acidification 346 
rate (Figure 5C). Mitochondrial coupling efficiency did not show any significant change 347 
(Supplementary Figure 5B). Figure 5D verifies these results in an oxygen consumption rate 348 
versus extracellular acidification plot (OCR/ ECAR), showing a weakening in metabolic 349 
activity in A5+/-;Kras cells. This is indicated by the movement of the A5+/-;Kras cell line 350 
measurements towards both, lower OCR and lower ECAR, demonstrating decreased ATP 351 
turnover. Interestingly, cellular fractionation experiments revealed a displacement in the 352 
mitochondrial fraction as detected by GLDH-activity. In particular, mitochondria were shifted 353 
towards the autophagosomal fraction, indicating decreased integrity of mitochondria (Figure 354 
5E). Finally, mRNA expression levels of Nrf1 and mitochondrial Sod2 were increased 355 
corroborating the elevated mitochondrial stress (Figure 5F); Nrf2 and cytosolic Sod1 were 356 
not changed (Supplementary Figure 5C). 357 
Concluding, monoallelic loss of Atg5 affects cellular homeostasis by altering mitochondrial 358 
morphology and compromising mitochondrial function. 359 
 360 
Atg5 level influences intracellular Ca2+ flux and extracellular cathepsin activity. 361 
Mitochondria play an important role in buffering intracellular Ca2+ levels and are thus closely 362 
linked to Ca2+ fluctuations. In addition, Ca2+ responses influence mitochondrial function/ 363 
morphology, gene transcription 13-15, vesicle trafficking, cellular migration, and lamellipodia 364 
formation at the front of migrating cells 16. Thus, we examined in more detail cellular Ca2+ 365 
responses as a putative mechanism connecting our observations. In support, Ca2+ 366 
responses of Kras and A5+/-;Kras cells after treatment with 0.01 or 0.05% FBS were 367 
significantly different (Figure 6A). Cytosolic Ca2+ responses in A5+/-;Kras cells were 368 
characterized by higher amplitudes and only one peak of Ca2+ elevation. Moreover the 369 
number of FBS-responding cells was slightly elevated in A5+/-;Kras versus Kras cells 370 
(Supplementary Figure 6A). S100a4, a Ca2+ - binding protein associated with increased 371 
metastatic capacities, was found highly expressed in A5+/-;Kras tumors compared to only a 372 
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low-level expression in Kras tumors. The higher PanIN orders and established PDAC-373 
structures were particularly positive for S100a4 expression (Figure 6B).  374 
Lysosomal trafficking and exocytosis of lysosomal cathepsins is also regulated by 375 
intracellular Ca2+ fluctuations 17. Quantification of lysosomal cathepsin activities in cell 376 
culture supernatants revealed a significantly higher activity of cathepsin L and cathepsin D 377 
(Figure 6C), whereas cathepsin B was not affected (Supplementary Figure 6B). Protein 378 
levels of the respective pro-cathepsins also showed a tendency towards increased amounts 379 
in A5+/-;Kras cells (Supplementary Figure 6B). In addition, copy number of genes associated 380 
with lysosomes indicated a difference in regulation between normal pancreas and pancreatic 381 
cancer samples (Supplementary Figure 6D).  382 
Furthermore, we functionally evaluated the importance of extracellular cathepsin activity in 383 
cell spreading and invasion. For this we treated Kras and A5+/-;Kras cells with the cathepsin 384 
inhibitor E64d, and quantified the number of filopodia per sphere (Figure 6D) and the number 385 
of matrigel invaded cells (Figure 6E). While the number of colonies formed by Kras and A5+/-386 
;Kras cells did not change after E64d-treatment (Supplementary Figure 6C), cell spreading 387 
and invasive capacities were significantly reduced in A5+/-;Kras cells (Figure 7D, 7E). Of 388 
note, E64d did not affect filopodia formation and invasive capacities of Kras cells (data not 389 
shown). 390 
In summary, levels of Atg5 significantly influence cellular Ca2+ responses and lysosomal 391 
enzyme activities, which are required for increased cell spreading and invasion. 392 
 393 
Monoallelic loss of Atg5 induces pro-tumorigenic inflammation 394 
Changes in inflammation have been shown to promote tumorigenesis and cancer cell 395 
invasion/ metastasis. Our transcriptomic results identified alterations in inflammatory 396 
pathways. Moreover, extracellular arginine levels, known to influence pro-tumorigenic- 397 
versus pro-inflammatory M1-macrophages, were increased in A5+/-;Kras versus Kras cells. 398 
Thus, we aimed to elucidate the effect of Atg5-monoallelic loss on macrophage-mediated 399 
inflammation. Firstly, we examined the cytokine/ chemokine profile of Kras and A5+/-;Kras 400 
cells in cell culture supernatants (Supplementary Figure 7A). Quantification of dot plot-pixel 401 
intensity revealed upregulation of cytokines involved in macrophage chemoattraction 402 
(CXCL1, CXCL12), M2-differentiation (M-CSF, CXCL12, IL10, CXCL2, IL1ra, CXCL10), and 403 
tumor progression/ metastasis (TNFa) in A5+/-;Kras versus Kras cells, while cytokines 404 
important for M1-polarization (GM-CSF), M1-chemoattraction (sICAM-1), and granulocyte 405 
attraction (G-CSF) were downregulated. To analyze in more detail the effect of Kras and 406 
A5+/-;Kras cells on the inflammatory microenvironment, we treated undifferentiated 407 
macrophages with the cell culture supernatants of Kras and A5+/-;Kras cells and 408 
characterized the changes in macrophage morphology, as described previously 18. 409 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
 14 
Supernatants from Kras cells induced macrophage differentiation into the M1-subtype; 410 
supernatants form A5+/-;Kras cells on the other hand shifted differentiation towards the M2-411 
subtype, (increased cell elongation, Supplementary Figure 7B), confirmed by elevated levels 412 
of Arginase 1 expression (Supplementary Figure 7B). Moreover, we assessed the in vivo 413 
ability of Kras and A5+/-;Kras cells to attract macrophages by quantifying F4/80 and CD206 414 
in the original pancreatic tumor tissues of these mice (Supplementary Figure 7C). 415 
Importantly, F4/80- and CD206-macrophage numbers were clearly elevated in A5+/-;Kras 416 
tumors, indicating more CD206 and thus M2-macrophages after monoallelic loss of Atg5. 417 
More F4/80 and Arginase 1-positive M2-macrophages were also attracted into the lungs of 418 
mice after tail vein injection of A5+/-;Kras compared to Kras cells (Supplementary Figure 419 
7D), further supporting the in vitro and in vivo results (Supplementary Figure 7B, C). 420 
To determine if macrophages critically influence the metastatic capabilities of A5+/-;Kras 421 
cells, we depleted macrophages in wildtype mice using liposomal-clodronate. Subsequently, 422 
we performed tail vein injection of A5+/-;Kras cells and analyzed lung tissue metastasis. 423 
Clodronate treatment was able to deplete most on the macrophages, as shown by F4/80 424 
immunohistochemistry (Supplementary Figure 7E, right). Interestingly, macrophage depletion 425 
significantly reduced metastasis of A5+/-;Kras cells compared to control liposome-treated 426 
mice, highlighting the importance of infiltrating macrophages in potentiating metastasis. 427 
Consequently, monoallelic loss of Atg5 induces changes in cytokine/ chemokine secretion 428 
from tumor cells resulting in accumulation of M2-macrophages ultimately shaping the 429 
inflammatory microenvironment to critically favor tumor aggressiveness and promote tumor 430 
metastasis. 431 
 432 
Levels of ATG5 are correlated to human pancreatic cancer aggressiveness 433 
To establish a connection between the mouse model results and human pancreatic cancer 434 
we analyzed ATG5 protein levels in three independent patient cohorts (Supplementary 435 
Tables 2, 3, 4). ATG5-ATG12 protein expression in lysates from pancreatic tumor patients 436 
(Cohort 1) was different between the samples (Figure 7A, top). Grouping the patients into 437 
ATG5 high versus ATG5 low-moderate expression indicated a trend towards reduced 438 
survival in the low-moderate ATG5-expression group (Figure 7A, bottom). Due to the 439 
variations in tumor cellularity and the limitations of western blotting, we performed ATG5 440 
immunohistochemistry (Cohort 2 and Cohort 3). As expected and already described 441 
(ProteinAtlas), ATG5 is expressed not only in the pancreatic epithelial tumor structures but 442 
also in other cell types (e.g., endothelial and islet cells) in the tissue (Figure 7B). After 443 
establishing an ATG5-expression score (Score 1, Score 2, Score 3), we divided the patients 444 
into low-moderate (Score 1, Score 2) and high (Score 3) ATG5 expression (Figure 7B). 445 
Applying this analysis on a small distant metastatic patient cohort (Cohort 2) showed a higher 446 
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metastasis incidence in the low-moderate ATG5 expressing patients (Figure 7C). 447 
Furthermore, we could significantly correlate reduced survival with lower ATG5 expression in 448 
a larger cohort of patients undergoing pancreatic cancer resection (Cohort 3, Figure 7D). 449 
Because lymph node and resection status was not different between the groups, ruling out 450 
important confounding factors (Figure 7D), these analyses very likely reflect the re-451 
occurrence of metastases and thus aggressiveness of the tumors. Of note, metastatic 452 
relapse in resected patients determines survival. Finally, TCGA-databank analysis identified 453 
a reduction in ATG5 copy numbers between pancreatic cancer samples and normal human 454 
pancreas (Figure 7D).  455 
Thus, lower levels of ATG5 are associated with increased pancreatic cancer metastasis and 456 
patient survival. 457 
 458 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
 16 
DISCUSSION: 459 
 460 
Autophagy has been shown to play a dual role in tumorigenesis of different tissue types 3, 19. 461 
Particularly, autophagy seems to accelerate tumor initiation while blocking progression of 462 
pre-neoplastic lesions, as exemplified in PDAC 2. Studies have mainly made use of models 463 
with complete loss of autophagic function, a fact that is rarely seen in human patients. 464 
Therefore, we aimed to analyze the effect of varying levels of Atg5 on PDAC development. 465 
Surprisingly, complete loss of Atg5 blocks tumorigenesis, while monoallelic loss of Atg5 466 
promotes tumorigenesis and metastasis. We suggest cell intrinsic changes in mitochondrial 467 
homeostasis, Ca2+ responses, autophagy regulation, and lysosomal cathepsin activation as 468 
well as changes in the inflammatory tumor microenvironment to be crucial for 469 
aggressiveness of pancreatic cancer. Importantly, shRNA-mediated Atg5-dosage regulation 470 
also increased metastatic capabilities of pancreatic cancer cells, indicating that a simple 471 
decrease in Atg5 levels is sufficient to influence PDAC metastasis. The clinical significance 472 
of this observation is supported by the analysis of three independent human pancreatic 473 
cancer cohorts verifying an association between ATG5 levels, PDAC metastasis and patient 474 
survival. 475 
Autophagy is closely connected with PDAC and multiple pathways influence this interaction, 476 
e.g., ROS-levels, ER-stress, hypoxia, mitochondrial metabolism, and the surrounding tumor 477 
microenvironment 2. Past studies have shown that the interplay between oncogenic Kras and 478 
autophagy during PDAC progression is also regulated by other genetic alterations, but 479 
contradictory results did not enable clear conclusions 4, 5. Our initial analysis of sequential 480 
pancreatic cancer stages implicated targeted induction of autophagy during PDAC 481 
development, confirming past results on gradual elevation of baseline autophagy during 482 
carcinogenesis 2. The importance of autophagy in pancreatic cancer progression was further 483 
verified by homozygous deletion of Atg5, confirming past results 4. Along the same line, 484 
whole-body inhibition of autophagy was recently shown to control tumor cell growth via 485 
intrinsic and extrinsic mechanisms in mice 20. Unlike complete loss of Atg5, however, 486 
monoallelic loss resulted in a higher tumor incidence and metastasis occurrence. Atg5-487 
dosage regulation through shRNA-mediated knock down also enhanced metastatic 488 
capabilities of pancreatic cancer cells, indicating that although there is a clear phenotypic 489 
difference between complete presence, partial presence, and complete absence of Atg5, the 490 
phenotypic effect follows Atg5-dosage in a non-linear fashion. So far, only one published 491 
study has uncovered a connection between monoallelic deletion of Atg5 and increased 492 
metastasis in melanoma supporting our results 21. Nonetheless, the underlying mechanisms 493 
for the phenotype in melanoma are still obscure. 494 
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Atg5, as apart of the Atg-conjugation system, is required for autophagic flow. Atg-mediated 495 
closure of autophagosomes is necessary for subsequent lysosomal degradation and 496 
recycling of membrane components 22. Upon complete loss of Atg5 in the pancreas, 497 
autophagosomes accumulate in acinar cells and degradation is blocked 11. However, the 498 
impact of Atg5 monoallelic loss on autophagic flux remains unclear. In A5+/-;Kras cells and 499 
tumors we detected decreased Atg5 protein expression. Interestingly, reduced protein 500 
amounts did not result in an apparent negative consequence on autophagy as A5+/-;Kras 501 
cells were more resistant to autophagy inhibitors or activators and functionally not affected. 502 
Multiple non-canonical autophagy and intracellular degradation pathways exist that might 503 
compensate for monoallelic loss of Atg5 (e.g., microautophagy, chaperone-mediated 504 
autophagy, non-canonical autophagy independent of various core autophagy proteins, 505 
selective autophagy, macropinocytosis) 23, 24. In order to fully illuminate the effect of 506 
monoallelic Atg5-loss on autophagy-associated pathways and to extent pancreatic tumor 507 
progression, more future studies are required. Therefore, our present results show that 508 
monoallelic loss of Atg5 enhanced autophagy levels in a cell-intrinsic manner, indicating 509 
active adaptation of pancreatic cancer cells. 510 
Loss of one allele of Atg5 significantly changed not only autophagy regulation, but also tumor 511 
cell behavior by enhancing migration and invasion. Importantly, Atg5-heterozygous cell lines 512 
could form tumors in hosts and had a higher capacity to metastasize to distant organs. 513 
Metastasis is a multistep process involving a plethora of cellular adaptations 25. Mitochondria 514 
26, Ca2+ oscillations 27, extracellular matrix degradation 28, and the tumor microenvironment 515 
29 have been shown to determine tumor malignancy and dissemination. Interestingly, we 516 
could detect changes in mitochondrial homeostasis with loss of one allele of Atg5. 517 
Specifically, mitochondrial function was reduced, while distinct mitochondrial stress markers 518 
were upregulated. Mitochondrial turnover was also affected as more fission events could be 519 
documented along with an increase of mitochondrial mass in the autophagosomal fraction, 520 
indicating uptake of damaged mitochondria. Past studies have shown that increased 521 
mitochondrial fission and fragmentation supports tumor cell growth, invasion, and migration 522 
26. Moreover, mitochondrial metabolism is necessary to support cancer cell dissemination, 523 
while a certain degree of cell stress is required for tumor cells to alter their mitochondrial 524 
programming and promote cellular adaptation 30-32. Mitochondria are also known to influence 525 
Ca2+ signaling amplitude and propagation rate by sequestering Ca2+. Especially in 526 
polarized pancreatic acinar cells, where a considerable portion of mitochondria are localized 527 
in the apical part of the cell, Ca2+ transients are effectively confined and spatially regulated 528 
13. Interestingly, intracellular Ca2+ fluctuations are involved in tumor cell dissemination 529 
influencing migration and vesicle trafficking 16, 33. Along these lines, monoallelic loss of Atg5 530 
influenced FBS-mediated migration/ invasion, FBS-induced Ca2+ responses as well as 531 
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expression of Ca2+ handling proteins. In support, Atg5 expression was recently linked to 532 
heightened tumor cell metastasis via disrupting the V1Vo ATPase, which is closely 533 
connected to cytosolic Ca2+, indicating a pathway through which a autophagy-related gene 534 
can promote metastasis in an autophagy-independent manner 34. Therefore, monoallelic loss 535 
of Atg5 might establish an intermediate stress level in tumor cells disturbing mitochondrial 536 
homeostasis and to a certain extent Ca2+ signaling, heightening their aggressive and 537 
metastatic potential.  538 
Tumor cell invasion further requires digestion of extracellular matrix, which can be achieved 539 
through lysosomal cathepsins 28. Lysosomes are highly responsive to changes in intracellular 540 
Ca2+ fluxes via expression of Ca2+ channels. One such channel is TRPM2, which is 541 
specifically activated by intracellular adenosine diphosphoribose (ADPR) 35. ADPR was 542 
elevated in A5+/-;Kras compared to Kras cells. Lysosomal Ca2+ signaling is connected to 543 
the autophagy process 36. In addition, lysosomes contain cysteine cathepsins, which are not 544 
only responsible for degradation, but also play a role in autophagy, metabolism, and 545 
lysosome-mediated cell death. Cathepsins regulate the numbers of autophagosomes and 546 
lysosomes 37. Our data pointed to a heightened level of autophagy in A5+/-;Kras cells. A5+/-547 
;Kras cells exhibited enhanced extracellular cathepsin activation. Importantly, cathepsin 548 
activation in the extracellular medium was required and sufficient to enable invasion of 549 
cancer cells. Monoallelic loss of Atg5 may in this scenario initiate multiple cellular changes 550 
starting with mitochondrial and Ca2+ homeostasis. Affected Ca2+ homeostasis may 551 
influence lysosomal numbers and fusions with autophagosomes, aggravated even further by 552 
the direct effects of Atg5 on autophagy levels. In addition, it was shown that the interaction of 553 
Atg5-Atg12 with the tethering factor TECPR1 (Tectonin Beta-Propeller Repeat Containing 1) 554 
is crucially involved in the initiation of autophagosomal/ lysosomal fusion to promote 555 
autophagic flux 38. In this context monoallelic loss of Atg5 could be tightly interrelated to 556 
impaired lysosomal biogenesis and fusion. A hindered autolysosomal maturation process 557 
may thus lead to an accidental activation of pro-cathepsins and subsequently their release 558 
into the extracellular medium ultimately promoting migration, invasion, and metastasis.  559 
Lysosomal homeostasis can also affect the immune system and cytokine secretion, 560 
especially in conjunction with cathepsin activities 39. The inflammatory tumor 561 
microenvironment is crucial in facilitating spontaneous PDAC development and amplifying 562 
the metastatic process. Anti-inflammatory M2-macrophages, regulatory lymphocytes, and 563 
neutrophils have been shown to potentiate PDAC 29, 40. Interestingly, we saw a shift in the 564 
cytokine profile of A5+/-;Kras cells towards cytokines involved in promoting pro-tumorigenic 565 
M2-macrophages. In support of all these data we also detected more M2-macrophages in 566 
the original A5+/-;Kras primary pancreatic tumors as well as in the lung tumors formed after 567 
tail vein injection of A5+/-;Kras cell lines. Importantly, depleting macrophages significantly 568 
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reduced A5+/-;Kras cell metastasis in vivo, highlighting the importance of macrophages in 569 
potentiating metastasis. Consequently, monoallelic loss of Atg5 leads to cell-intrinsic 570 
changes, which ultimately affect the tumor microenvironment favoring metastatic spread.  571 
So far, only the autophagy protein Beclin-1 has been found monoallelically deleted in a 572 
variety of cancer types, such as breast, ovarian, and prostate cancer. In support of these 573 
findings Beclin-1 heterozygous mice display frequent spontaneous malignancies 41. Our 574 
study expands the spectrum of monoallelically affected autophagy genes to Atg5, correlating 575 
ATG5 protein expression with metastasis and survival in three independent human 576 
pancreatic cancer cohorts. Clinical trials on pancreatic cancer patients are currently 577 
evaluating autophagy inhibitors such as chloroquine in adjuvant therapies combined with 578 
gemcitabine (NCT01777477 42). However, autophagy inhibitors are not only less specific, but 579 
very likely to only partially impede autophagic flux 43. As we have shown that monoallelic loss 580 
of Atg5 leads to chloroquine resistance and higher metastatic spread, administration of 581 
chloroquine may thus generate resistant cancer cell clones with heightened aggressiveness. 582 
Therefore, our data alert towards increased awareness when applying autophagy blockers in 583 
clinical trials for pancreatic cancer patients. 584 
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Figure 1: Monoallelic loss of Atg5 influences metastatic load.  688 
(A) Autophagy in the pancreas of GFP-LC3 transgenic mice under normal conditions and 689 
during PDAC progression in GFP-LC3;Kras mice. Tumor and liver metastasis are shown; 690 
white square/ white asterisk indicate ADM/ PanIN-adjacent acinar cells (DA=DAPI). (B) 691 
Representative pictures of pancreatic, liver, and lung tumors from Kras and A5+/-;Kras mice; 692 
black arrowheads/ asterisk point to metastatic focus in liver/ lung respectively. (C) Tumor 693 
incidence (%) in Kras (n=54), A5+/-;Kras (n=12), and A5;Kras (n=24) mice. (D) Metastasis 694 
incidence (%) in Kras (n=31) and A5+/-;Kras (n=10) mice. Scale bars equal 50μm. 695 
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 24 
Figure 2: Monoallelic loss of Atg5 affects cellular responses to autophagy activators 698 
and inhibitors. 699 
(A) Immunohistochemistry and scoring (score 1 (faint) - score 3 (strong)) of Atg5, LC3, and 700 
p62 in Kras and A5+/-;Kras mouse tumors; asterisks highlight tumor structures and 701 
arrowheads tumor microenvironment; Atg5-detection in primary pancreatic tumor cells 702 
isolated from Kras, A5+/-;Kras, and A5;Kras mice. (B) Morphology of A5+/-;Kras and Kras 703 
cells (left); Kras and A5+/-;Kras proliferation curve showing cell number x104 versus time 704 
(hours) after seeding (n=3) (right). (C) Colony formation assay in Kras and A5+/-;Kras cells 705 
after cultivation in 10% FCS-containing medium (F)/ HBSS-starvation (H) (n=3) (left); 706 
representative picture of colony formation capacity in Kras and A5+/-;Kras cells after HBSS-707 
starvation (right). (D) Phospho-AMPKa, LC3-I/ LC3-II, and p62 expression in Kras and A5+/-708 
;Kras cells, after FCS-starvation, with/ without chloroquine treatment (CQ) (left); 709 
representative picture of colony formation capacity in Kras and A5+/-;Kras cells after CQ-710 
treatment (right). (E) Cyto-ID fluorescence in Kras and A5+/-;Kras cells after cultivation in 711 
medium with/ without FCS (n>3). Mean±SD, *P<0.05, ***P<0.001. Scale bars equal 50μm 712 
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 25 
Figure 3: Monoallelic loss of Atg5 increases metastatic properties of cancer cells in 715 
vitro and in vivo. 716 
(A) Anoikis assay with Kras and A5+/-;Kras cells (%). (B) Quantification of migration (left), 717 
invasion (middle), and filopodia numbers/ sphere with representative picture of cell 718 
spreading/ filopodia formation in Kras and A5+/-;Kras cells (right). (C) Lung tumors after tail 719 
vein injection (i.v.) of Kras and A5+/-;Kras cells; black arrowheads indicate tumors or BrdU-720 
positive cells (top); quantification of lung metastasis (% area) after i.v. of Kras and A5+/-;Kras 721 
cells (n=6) (bottom). (D) Western blot of Atg5-Atg12 and LC3I/II in Kras, A5+/-;Kras and Kras 722 
cells after 54, 58, 81, 86, 94% shRNA-mediated knockdown of Atg5. (E) Migration (left), 723 
invasion (right) of Kras versus Kras cells with 58, 94% knockdown (KD) of Atg5. (F) 724 
Quantification of lung tumor formation after tail vein injection (i.v.) of Kras and Kras cells with 725 
58, 94% knockdown (KD) of Atg5 (% area); representative H&E pictures are included. 726 
Mean±SD (n>3), ***P<0.001, **P<0.01. Scale bars equal 50μm. 727 
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Figure 4: Monoallelic loss of Atg5 leads to global changes in metabolism, 730 
inflammation, and vesicle homeostasis. 731 
(A) Normalized enrichment score (NES) versus significance plot illustrating gene sets, 732 
identified by GSEA, enriched in either Kras or A5+/-;Kras pancreatic tumor cells (n=3); 733 
enriched pathways are localized beneath dotted line. (B) Functional classification of most 734 
highly regulated genes identified by GSEA in Kras and A5+/-;Kras cells (% of all significantly 735 
upregulated genes; Supplementary Figure 4C). (C) Classification of significantly enriched 736 
gene sets into categories for Kras (left) and A5+/-;Kras (right) cells (P value 0.0 indicates 737 
P<0.001). (D) Classification of significantly upregulated metabolites in Kras and A5+/-;Kras 738 
cells (left) and their supernatants (media, right); amino acids/ peptides=red, lipids=black, 739 
nucleotides/ carbohydrates=purple; Mean±SD (n=3). 740 
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Figure 5: Monoallelic loss of Atg5 reduces mitochondrial functionality and increases 743 
ER-stress. 744 
(A) TEM pictures of Kras and A5+/-;Kras cells (4000x, 20000x); asterisk/ black arrowhead 745 
indicate mitochondria/ mitochondrial fission. (B) Oxidative capacity (pmolO2/min) of Kras and 746 
A5+/-;Kras cells normalized to protein or DNA (ng) (n≥30). (C) Glycolytic capacity (mpH/min) 747 
of Kras and A5+/-;Kras cells normalized to protein or DNA (ng) (n=9). (D) Oxygen 748 
consumption rate (pmolO2/min/ng DNA) versus extracellular acidification rate (mpH/min/ng 749 
DNA) for Kras and A5+/-;Kras cells. (E) Mean glutamate dehydrogenase activity (GLDH, 750 
mU/mg protein) distribution into density fractions (with decreasing density from 22 to 46) in 751 
Kras and A5+/-;Kras cell extracts (n=4). (F) qRT-PCR of Nrf1 and Sod2 normalized to 752 
cyclophilin (n=3). Mean±SD, *P<0.05, **P<0.01. 753 
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Figure 6: Atg5-dependent changes in Ca2+ signaling, extracellular cathepsin levels 756 
and filopodia formation: determinants of metastatic potential. 757 
 (A) Representative recordings (left) and amplitude (right) of cytosolic Ca2+ responses (as 758 
described in Supplementary Methods) in Kras and A5+/-;Kras cells after FBS-stimulation (at 759 
200sec, marked with black arrowhead) (n>170). (B) S100a4 immunohistochemistry in Kras 760 
and A5+/-;Kras mice. (C) Cathepsin L (CTSL) and Cathepsin D (CTSD) extracellular activity 761 
(% extracellular activity versus total activity) as measured from supernatants of Kras and 762 
A5+/-;Kras cells (n=15). (D) Quantification of filopodia numbers/ sphere in A5+/-;Kras cells 763 
after E64d treatment compared to no treatment (NT) (n>3) (left); representative bright field 764 
picture of cell spreading and filopodia (right). (E) Quantification of invaded A5+/-;Kras cells 765 
after E64d treatment or no treatment (NT) (n>3) (left); representative picture of invaded cells 766 
(right). Mean±SD, *P<0.05, **P<0.01, ***P<0.001. Scale bars equal 50μm. 767 
 768 
  769 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
 29 
Figure 7: Lower levels of ATG5 gene and protein levels correlate with human 770 
pancreatic cancer aggressiveness. 771 
(A) ATG5-ATG12 protein levels in human pancreatic cancer samples (top); Kaplan-Meier 772 
survival analysis (months) with Cohort 1 patients separated into high (ATG5/ β-Actin ratio 773 
equal/ above 0,5; n=22, median survival 20,5 months) versus low-moderate (ATG5/ β-Actin 774 
ratio below 0,5; n=34, median survival 12,5 months) ATG5 expression groups (P=0.4479). 775 
(B) Representative ATG5 immunohistochemistry in primary human PDAC tissues separated 776 
into Score 1/ 2 (low-moderate) and Score 3 (high); asterisk/ arrowhead/ circle mark epithelial 777 
cancer/ endothelial/ islet cells. (C) Distant metastasis incidence (%) in n=23 Cohort 2 778 
patients separated into high (n=6) versus low-moderate (n=23) ATG5 expression groups 779 
according to (B). (D) Kaplan-Meier survival analysis (days) with Cohort 3 patients separated 780 
into high (n=23, median survival 407 days) versus low-moderate (n=56, median survival 781 
358,5 days) ATG5 expression groups according to (B) (*P=0.0396, top); table shows lymph 782 
node infiltration (%, pN0, pN1) and resection status (%, R0, R1) (bottom). (E) Illustration of 783 
autophagy-associated DNA copy number gain (red) or loss (blue) (TCGA data) in normal 784 
versus pancreatic cancer (PC) samples; blue bars correlate to less than hemizygous, white 785 
to hemizygous, and red to more than hemizygous levels. Scale bars equal 50μm. 786 
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“What You Need to Know”: 
Background and Context: Autophagy is considered a therapeutic target in PDAC. 
As the effect of autophagy pathway inhibition remains unclear, the authors 
investigated the role of Atg5, an important autophagy regulator, in PDAC. 
New Findings: The authors correlate PDAC-malignancy with Atg5 levels in mice and 
patients. Reduced Atg5 levels enhance PDAC-aggressiveness in vitro and in vivo 
through mechanisms including cathepsin activation and pro-tumorigenic M2-
macrophage infiltration. 
Limitations: Reduction of Atg5-levels influences a multitude of cellular functions 
collectively promoting PDAC-progression and -metastasis. Future studies may need 
to analyze the exact contribution of each of these pathways in PDAC. 
Impact: Autophagy pathway inhibitors are utilized in PDAC-treatment. However, 
caution is required as the authors for the first time correlate reduced levels of an 
autophagy pathway regulator with metastasis/ patient survival. 
 
“Lay Summary”:  
Monoallelic loss of Atg5 in PDAC enhances metastatic capacities of cancer cells 
through activating extracellular cathepsins and attracting pro-tumorigenic M2-
macrophages collectively favoring PDAC malignancy. 
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SUPPLEMENTARY MATERIALS AND METHODS: 
 
Quantification of relative pancreatic weight, tumor incidence, and metastasis 
incidence 
Kras, A5+/-; Kras, and A5; Kras mice were sacrificed at 4, 9, and 18 weeks of age or at the 
time point of sickness. Relative pancreatic weight was calculated from the pancreas and 
body weight obtained during sacrifice (pancreas weight/ body weight). Tumor incidence and 
metastasis incidence (% of tumor or metastasis-positive mice relative to all mice sacrificed) 
was calculated after histological examination. Metastasis-positive mice were mice with 
metastasis in liver, lung, or diaphragm from the pool of pancreatic tumor-positive mice. 
Ascites, lymph node, spleen, or kidney infiltration was also evaluated (see Supplementary 
Table 1). 
 
Detection of GFP-LC3 puncta 
GFP-LC3 mice with or without concomitant Kras expression were sacrificed after standard 
fed conditions. Pancreas was snap frozen in freezing medium (Tissue-Tek O.C.T. 
Compound, Weckert Labortechnik, Germany) and 7-10mm thick cryo-sections were mounted 
on adhesive-coated slides. Sections were air dried, fixed in 100% ethanol for 8 minutes at 
RT, washed with PBS and covered with DAPI containing mounting medium (H-1200 Vector 
Laboratories, CA). Sections were processed and kept in the dark until analysis. Puncta 
formation was detected by analysis of green fluorescence (EX/EM 470/525nm) with 
fluorescence microscopy (Zeiss Axiovert 200M).  
 
Tumor cell isolation and cultivation 
Primary pancreatic tumor cell lines were established from isolated murine pancreatic tumors. 
To establish the cell lines, pieces of pancreatic tumor tissue from Kras, A5+/-; Kras, and A5; 
Kras mice were placed in full culture medium (see below) and tumor cells were allowed to 
grow out of the tissue. Cell lines were routinely cultured under standard conditions (5% CO2, 
37 C) in culture media (Dulbecco’s modified Eagle medium (DMEM) supplemented with 
10%FBS (#10082147; Gibco), 1% PenStrep (#1500-063; Gibco), 1% Non-Essential-Amino-
Acids (NEAA #11140050; Gibco)). On average, cells were passaged 5 times prior to any 
experiments. 
 
Knockdown of mAtg5 
Experimental procedures were followed as described previously 1. Briefly: 
 
Transfection of 293T cells for production of lentiviral particles 
??????????????????? ??????????????????????????????????????????????????????????????? ????????????????????????????????
5 x 106 293T cells were seeded in 10 cm dishes. After one day, media was replaced and co-
transfection of transfer plasmids purchased from Sigma Aldrich (TRCN0000327456 (54% 
knockdown, validated), TRCN0000327358 (58% knockdown, validated), TRCN0000363558 
(81% knockdown, validated), TRCN0000375754 (86% knockdown, validated), and 
TRCN0000099432 (94% knockdown, validated)) with lentiviral packaging plasmids 
(pMD.GP, pRSV-rev, pMD.G) was performed using lipofectamine 2000 (Thermo Fisher 
Scientific). shRNA that does not target any known human or mouse gene (shNT) was used 
as a control. Two days later, lentiviral particles were harvested from the supernatant and 
frozen at -80°C. 
 
Transduction of target cells with mATG5 knockdown constructs 
Target Kras cells were seeded in 6 cm dishes. One day later, media was aspirated and 1 ml 
of lentiviral suspension was added to cells in presence of 8 µg/ml Polybrene (Sigma Aldrich). 
After 2 h at 37°C, 4 ml media was added. Selection of transduced cells was performed using 
10 µg/ml puromycin.  
 
Experimental analysis 
Cells were tested in western blotting for Atg5, LC3, and β-Actin expression (as described 
below) and the knockdown percentage was confirmed. Cells with 54%, 58%, 81%, 86%, and 
94% mAtg5-knockdown were further used in colony formation (full medium, 10% FCS), 
Boyden Chamber migration, invasion, and tail vein injection experiments as described below. 
Experiments were performed in triplicates. 
 
In vitro cathepsin activity measurements 
Activities of cathepsins B, L, and D were intra- and extracellularly assessed in cell lysates 
and culture media of primary pancreatic tumor cell lines. Tumor cells were separated from 
culture media by centrifugation at 1000 g for 10 min. Then, cell pellet and culture medium 
were snap frozen. After thawing tumor cells were subsequently resuspended in ice-cold 
homogenization buffer (5 mM MOPS pH 6.5, 250 mM sucrose, 1 mM Mg2SO4, 0.13% Triton 
X100l) and lysed by sonication. Cathepsin B and -L were determined as Ca074- and N1760- 
sensitive activity in assay buffer (50 mM sodium phosphate buffer [pH 5.5], 1 mM EDTA, and 
1 mM dithiothreitol) using the fluorogenic substrates Z-Arg-Arg-7-amino-4-methylcoumarin A 
(10µM, #31213-v, Pepta Nova) and Z-Phe-Arg-7-amino-4-methylcoumarin (10µM, #3095-v, 
Pepta Nova), respectively. Cathepsin D activity was measured in 50 mM sodium acetate 
buffer pH 4.0 using the fluorogenic substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-
Lys(Dnp)-D-Arg-NH2 (10µM, #3200-v, Pepta Nova). The release of 7-amido-4-
methylcoumarin was kinetically monitored over 10 minutes at the excitation/emission 
wavelength of 360/438 nm in a Safire microplate reader (Tecan, Grödig, Austria) by 
spectrofluorometry. Intra- and extracellular portions of cathepsin activities were normalized to 
the protein concentration in cell lysates determined by BioRad protein Assay kit. 
 
Subcellular fractionation by isopycnic Percoll density centrifugation and 
measurement of GLDH activity 
To analyze distribution and integrity of mitochondria in subcellular fractions pelleted tumor 
cells harvested from primary pancreatic tumor cells lines (produced as described above) 
were resuspended in HS buffer (250mM sucrose, 10 mM citric acid, 0.5 mM EGTA, 0.1 mM 
MgSO4 [pH 6.0]) and homogenized by 5 strokes using a Dounce homogenizer. After 
centrifugation at 100g post-nuclear supernatant was applied onto an isotonic 50% (v/v) 
Percoll/HS buffer solution (described above) at pH 7.27 and subsequently separated by 
isopycnic centrifugation at 50,000 g for 45 min at 4°C. After separation the percoll gradient 
was portioned in 46 fractions using a peristaltic pump beginning from the bottom and 
fractions were stored at -80°C until further use.  
Activity of GLDH as a marker of mitochondrial distribution in subcellular fractions was 
determined spectrophotometrically at 340 nm according to NADH2 oxidation with 2-
oxoglutarate and NH4+ as a substrate by the method of E. Schmidt 2. 
 
Immunoblotting 
For immunoblotting, Kras, A5+/-; Kras, and A5; Kras cells were pelleted and snap frozen. 
Cell pellets were resuspended in ice cold protein lysis buffer (50mM HEPES pH 7.9, 150mM 
NaCl, 1mM EDTA pH 8.0, 0.5% NP-40 (Roche), 10% Glycerol) supplemented with 
protease/phosphatase inhibitors (SERVA), sonicated, and kept on ice. Extracellular proteins 
secreted into the culture medium were concentrated by trichloroacetic acid precipitation 
(TCA, final concentration 6 %) in the presence of 2% Na-deoxycholate by the method A. 
Bensadoun3. Concentration was determined by BioRad protein Assay kit and concentration 
Laemmli 
buffer (300 mM Tris-HCl, pH 6.8, 10% (w/v) SDS, 50% (v/v) Glycerol, 0.05% (w/v) 
Bromphenole blue, 5% (v/v) β-mercaptoethanol) except when used for detection of 
mitochondrial oxidative phosphorylation complexes. Protein lysates were separated by SDS-
gel electrophoresis and transferred to PVDF membranes. Following over night incubation 
with primary antibody at 4°C, proteins were detected using horseradish peroxidase-
conjugated secondary antibodies anti-mouse (NA931V GE Healthcare Life Sciences), anti-
rabbit (NA934V GE Healthcare Life Sciences) or anti-guinea pig (A7289 Sigma) and ECL 
reagent (Amersham). The primary antibodies used include: Anti-Atg5 (1/1000) (NB110-
53818 Novus Biologicals), anti-p62 (1/1000) (GP62-C Progen), anti-LC3 (1/1000) (PD014 
MBL International), anti-Cathepsin B (1/5000) (AF965, R&D Systems), anti-p53 (1/500) 
(NCL-p53-CM5p Novocastra), anti-Cathepsin L (1/5000) (AF1515, R&D Systems) anti-
Cathepsin D (1/5000) (cs-10725, Santa Cruz Biotechnology), anti-phospho-AMPKa (1/1000) 
(2535 Cell Signaling Technology), anti-AMPKa (1/1000) (2532 Cell Signaling Technology), 
anti-phospho-S6 (1/1000) (2211 Cell Signaling Technology, anti-SOD2 (1/1000) (ADI-SOD-
111 Enzo), anti-BiP (1/1000) (AB21685 Abcam), anti-MitoProfile Total OXPHOS Rodent 
Western Blot antibody cocktail (1/1000) (MS604 Mitosciences), -β-Actin (1: 2000) 
(A5441, Sigma). 
 
Histochemistry and immunohistochemistry 
For proliferation analysis mice were labeled with 50mg of BrdU (B5002 Sigma) per g body 
weight by intraperitoneal injection and sacrificed 2h later. Pancreas was fixed in 4% (wt/vol) 
paraformaldehyde in PBS overnight at 4°C and embedded in paraffin wax. Tissue sections of 
2mm thickness were mounted on adhesive-coated slides and stained with H&E. 
For immunohistochemistry standard procedures were applied. Briefly, after deparaffinization 
and rehydration, heat-induced antigen retrieval with 0,01M citrate pH 6.0 was utilized. 
Endogenous peroxidase was blocked with 3% hydrogen peroxide for 15min at RT in the 
dark. Unspecific binding was blocked with 5% serum for 1h at RT. Slides were incubated with 
primary antibodies diluted in blocking solution over night at 4°C. Primary antibodies used 
include: anti-BrdU (1/250) (MCA2060 AbD Serotec), anti-F4/80 (1/100) (MF-48000 
Invitrogen), anti-CK19 (1/200) (TROMA III Developmental Studies Hybridoma Bank), anti-
Arginase 1 (1/500) (610708 BD Transduction Laboratories), anti-S100a4 (1/800) (13018 Cell 
Signaling Technology), anti-MMR/ CD206 (1/100) (AF2535 R&D systems Biotechne), anti-
Atg5 (1/100) (NB110-53818 Novus Biologicals), anti-p62 (1/100) (GP62-C Progen), and anti-
LC3 (1/100) (PD014 MBL International). Secondary antibodies including biotinylated anti-
rabbit in goat (BA 1000 Vector), anti-mouse in goat (BA 9200 Vector), and anti-rat in rabbit 
(BA 4000 Vector) were applied for 1h at RT and avidin-biotin peroxidase complex for 
biotinylated secondary antibodies was then added according to manufacturer directions 
(Vector Laboratories, CA). Staining was developed with DAB reagent (Vector Laboratories, 
CA). For Arginase 1 and S100a4 detection Streptavidin/Biotin blocking kit (SP2002 Vector) 
was used during the staining procedure to reduce background, according to manufacturer 
instructions. Hematoxylin was used for counterstaining. 
 
ADM and PanIN Quantifications 
Paraffin-embedded tissue sections from 4-week old Kras, A5+/-; Kras, A5; Kras were stained 
for H&E and photographed at 100x magnification. The number of Acinar to Ductal 
Metaplasias was determined in each picture using Zeiss axiovision software. Measurements 
from multiple photographs per tissue slide were summed up and expressed as ADM per High 
Power Field (HPF). Results were then averaged according to genotype. In a similar fashion, 
paraffin-embedded tissue sections from 9- and 18-week old Kras, A5+/-; Kras, A5; Kras were 
stained for H&E and photographed at 100x magnification. Pancreatic Intraepithelial 
Neoplasias (PanINs) were classified according to PanIN-1/-2/-3 and total numbers were 
expressed as PanIN/HPF. Results were then averaged according to genotype and age 
group. 
 
Co-immunofluorescence 
Cryo-sections of GFP-LC3 transgenic pancreas were processed as described above. 
Unspecific binding was blocked with 5% serum at RT and incubated over night at 4°C with 
the primary antibody. Anti-CK19 primary antibody (TROMA III Developmental Studies 
Hybridoma Bank) was diluted in blocking solution (1/200). At the following day secondary 
antibody anti-rat in goat Alexa Fluor 568 (1/300) (A11077 Invitrogen) was applied for 1h at 
RT. In the end, slides were covered with DAPI containing mounting medium (H-1200 Vector 
Laboratories) and analyzed with fluorescence microscopy (Zeiss Axiovert 200M).  
 
Transmission Electron Microscopy (TEM) 
For TEM Kras and A5+/-; Kras cells were collected and fixed in 2.5% electron microscopy 
grade glutaraldehyde in 0.1M sodium cacodylate buffer pH 7.4 (Science Services, Munich, 
Germany), postfixed in 2% aqueous osmium tetraoxide 4, dehydrated in gradual ethanol (30–
100%) and propylene oxide, embedded in Epon (Merck, Darmstadt, Germany) and cured for 
24 hours at 60°C. Pellets were cut in semithin sections and stained with toluidine blue. 
Ultrathin sections of 50nm were collected onto 200 mesh copper grids, stained with uranyl 
acetate and lead citrate before examination by transmission electron microscopy (Zeiss Libra 
120 Plus, Carl Zeiss NTS GmbH, Oberkochen, Germany). Pictures were acquired using a 
Slow Scan CCD-camera and iTEM software (Olympus Soft Imaging Solutions, Münster, 
Germany) 
 
RNA Extraction and Quantitative Real-Time Polymerase chain reaction (qRT-PCR) 
For RNA extraction, Kras and A5+/-; Kras cells were collected in RLT lysis buffer (1015762 
Qiagen) supplemented with 1% b-mercaptoethanol (M6250 Sigma) and snap frozen. 
Subsequently, RNA was extracted using the RNeasy Mini Kit (74104 Qiagen). SuperScript II 
Reverse Transcriptase (18064-014 Invitrogen) was used for complementary DNA (cDNA) 
synthesis. qRT-PCR was carried out using a StepOne Plus Real-Time PCR System (Applied 
Biosystems) in combination with Power SYBR Green PCR Master Mix (4368577 Applied 
Biosystems). Target mRNA expression was normalized to endogenous cyclophillin and 
quantified by the delta-delta CT method. Primer sequences are provided below.  
For detection of spliced Xbp1, cDNA was subjected to PCR with a primer set detecting both 
unspliced and spliced Xbp1 (unspliced Xbp1u 171 bp, spliced Xbp1s 145 bp). PCR products 
were separated by agarose gel electrophoresis. Cyclophilin was used as control. 
 
Gene Forward primer Reverse primer 
Sod1 GTCCGTCGGCTTCTCGTCT CACAACTGGTTCACCGCTTG 
Sod2 ACACATTAACGCGCAGATCA ATATGTCCCCCACCATTGAA 
Nrf1 TCTCACCCTCCAAACCCAAC CCCGACCTGTGGAATACTTG 
Nrf2 TTCTTTCAGCAGCATCCTCTCCAC ACAGCCTTCAATAGTCCCGTCCAG 
Xbp1 ACACGCTTGGGAATGGACAC CCATGGGAAGATGTTCTGGG 
Cyclophilin ATGGTCAACCCCACCGTGT TTCTGCTGTCTTTGGAACTTTGTC 
 
Microarray Data Analysis 
For transcriptomic analysis, Kras and A5+/-; Kras tumor cells were harvested after PBS-
washing in RLT lysis buffer supplemented with 1% b-mercaptoethanol, as described above. 
Cell suspensions were snap frozen and stored at -80°C. RNA isolation from tumor cell 
suspensions and Affymetrix GeneChip (Mus musculus) Mouse Gene 1.0 ST Array was 
conducted by the service facility KFB Center of Excellence for Fluorescent Bioanalytics 
(Regensburg, Germany, www.kfb-regensburg.de). Microarray data were analyzed by using 
the Gene Set Enrichment Analysis Software (GSEA) provided by the Broad Institute. A 
Nominal Enrichment Score (NES) of ≥1.0 and a nominal p-value of <0.05 were used to 
evaluate significantly upregulated pathways according to KEGG and Transcription Factor 
Binding Motif databases. Pathways were subsequently separated into groups depending on 
their description in the respective database. A heat map of the most highly regulated genes 
computed by GSEA was used and the genes were further classified according to their 
function. Genes belonging to one functional group were depicted as percentage related to 
the entire number of highly regulated genes. A NES versus nominal p value diagram was 
provided to indicate the total number of regulated (NES≥0.5) and significantly regulated 
(NES≥1.4, nominal p value< 0.05) pathways detected in the KEGG database. Microarray 
data are available in the ArrayExpress database at EMBL-EBI 
(https://www.ebi.ac.uk/arrayexpress/) under accession number E-MTAB-6275. 
 
Non-targeted metabolomic measurements 
LC-MS/MS–based non-targeted metabolomics analysis was conducted at the Genome 
Analysis Centre, Helmholtz Zentrum München as previously described 5. About 1x106 
pancreatic cancer cells were required for the analysis. In brief, 0.375x106 Kras or A5+/-; Kras 
cells were seeded in duplicates in a 6-well plate with 2 ml culture medium and grown for 48h 
until 80-90% confluent and an approximate number of 0.5x106 was reached. Cells were 
washed two times with PBS (37°C). Dry ice cold 80% v/v methanol (400 ml) containing 4 
recovery standard compounds to monitor extraction efficiency was added to the cells to 
cover them immediately. Cells were scraped and the cell suspension was transferred into 
precooled (dry ice) 2 ml screw cap micro tubes (Sarstedt Micro tube 2 ml, PP (Reference #: 
72.694.005)) filled with 160 mg glass beads. Another 100 ml of dry ice cold methanol 
extraction solvent to wash the well was added and transferred to the micro tube. 
Suspensions of two 6-wells were pooled into one tube to obtain a sample of 1x106 cells in 1 
ml cell suspension. The samples were stored immediately at -80°C until metabolomic 
analysis was performed. The metabolites were assigned to cellular pathways based on 
PubChem, KEGG, and the Human Metabolome Database. Metabolic pathways were 
described as significantly up- or down-regulated, when metabolites assigned to those 
specific pathways were increased or decreased, respectively. Values depicted correspond to 
the absolute values normalized in terms of raw area counts after LC/MS-based metabolomic 
analysis. 
 
Oncomine database 
The oncomine database (www.oncomine.org) was used to search for autophagy and 
lysosomal function-associated genes. GO Biological Process-Autophagy or GO Cellular 
Component-Lysosome was used as concept; primary filters selected were Cancer versus 
Normal Analysis and Pancreatic Cancer; pathology subtypes M1+, N1+, T4 according to 
TNM-staging were subsequently applied. DNA Copy Number (log2 copy number units) 
retrieved from the Cancer Genome Atlas (TCGA Research Network, 
http://cancergenome.nih.gov/) was used to illustrate copy number gain or loss in human 
pancreatic cancer samples versus normal pancreas samples.  
 
Measurement of mitochondrial metabolism by seahorse analyzer 
Measurements of oxygen consumption rate (OCR) were performed with a XF extracellular 
flux analyzer as described previously (Oelkrug R, Goetze N, Exner C, Lee Y, Ganjam GK, 
Kutschke M, Muller S, Stohr S, Tschop MH, Crichton PG, Heldmaier G, Jastroch M, Meyer 
CW. Brown fat in a protoendothermic mammal fuels eutherian evolution. Nature 
communications 2013;4:2140). Briefly, Kras and A5+/-;Kras tumor cells were seeded at a 
density of 1X105 cells per well in a XF24 cell culture microplate. DMEM (4.5 g/L glucose, +L-
Glutamine, -Pyruvate, pH 7.6 at RT) supplemented with 10% heat inactivated FBS (Gibco) 
and 1% Pen/Strep was used for cell culturing. On the day of assay (24h after seeding), 
medium was exchanged to non-carbonated Seahorse measurement medium and the XF24 
plate was transferred to a temperature-controlled (37 °C) XF24 Extracellular Flux analyzer 
(Seahorse Bioscience) and equilibrated for 10 min. To determine the basal respiration four 
assay cycles (1-min mix, 2-min wait and 3-min measuring period) were used. Then 
oligomycin (4 ?M) was added by automatic pneumatic injection (three assay cycles) to 
inhibit ATP synthase and thus approximate the proportion of respiration used to drive ATP 
synthesis versus proton leak-linked respiration. Oligomycin was followed by an injection of 
FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) (0.5  ? M) to completely 
dissipate proton motive force and maximally stimulate mitochondrial respiration (three assay 
cycles), thus determining spare respiratory capacity and substrate oxidation capacity. An 
injection of rotenone (4 ?M) and antimycin A (2 ?M) was used to correct for the non-
mitochondrial respiration rate (three assay cycles), which was subtracted from all the other 
rates. Coupling efficiency was calculated as the oligomycin-sensitive fraction of mitochondrial 
respiratory activity, estimating the proportion of basal respiration used to drive ATP 
synthesis. To determine extracellular acidification rates (ECARs) for glycolysis, experiments 
were ended by injection of 2-DG (2-deoxy-D-glucose, 100 mM), correcting for non-glycolytic 
acidification. Injection of 2-DG enabled calculation of glycolytic acidification. Data obtained 
after oligomycin treatment induce glycolytic capacity. OCR was plotted against ECAR to 
illustrate oxidative versus glycolytic metabolism in cancer cells. Raw data were normalized to 
either protein or DNA content (ng).  
 
Cell morphology analysis and quantification of cell proliferation 
To analyze cell morphology, Kras and A5+/-; Kras were seeded in 6-well plates. 24h after 
seeding, pictures were acquired with the Zeiss Axiovision Imager A1 using a magnification of 
100x. For quantification of proliferation, 5x104 Kras and A5+/-; Kras cells were seeded per 
well in a 6-well plate. The culture media was changed every other day. Cells were counted 
after trypsinization every 24 hours up to 120 hours using the neubauer counting chamber. 
Full medium Dulbecco’s modified Eagle medium (DMEM) supplemented with 10%FBS 
(#10082147; Gibco), 1% PenStrep (#1500-063; Gibco), 1%NEAA (#11140050; Gibco) was 
used for cell culture. 
 
Autophagic flux measurement using Cyto-ID 
To analyze autophagosome accumulation, Kras and A5+/-; Kras were seeded in triplicates in 
96-well plates and allowed to adhere overnight. Half of the cells were kept in full medium and 
compared to cells cultivated overnight in serum-free medium. Autophagosome accumulation 
was analyzed by using the CYTO-ID Autophagy Detection Kit (Enzo, ENZ-51031) according 
to the manufacturer’s instructions. Fluorescence was detected using a Varioscan Lux 
(Thermo scientific) microplate reader. 
 
Colony formation and cell treatments 
For the cologenic assay, 3x102 Kras and A5+/-; Kras cells were plated in triplicates six-well 
plates and grown for 10d in culture media. Colonies were stained with 2% crystal violet 
(C3886; Sigma), washed with water, and their area was quantified using ImageJ. Treatments 
during the clonogenic assays include: 10% FCS-containing medium, serum-free HBSS-
containing medium (Hanks´Balanced Salt Solution GIBCO-14025092, 1:20 dilution of normal 
medium), chloroquine in full medium (2µM and 6 µM, C6628 SIGMA), 6-Aminonicotinamide 
in full medium (10µM and SIGMA-A68203), Rotenone in full medium (15nM and SIGMA-
R8875), Galactose and Glutamine in glucose free medium (Galactose 10mM and Glutamine 
4mM, D-(+)-Galactose, SIGMA-G5388 and GlutaMAX-I, GIBCO-35050061, DMEM, no 
glucose, GIBCO-11966-025), High Glucose in glucose free medium (25mM and GIBCO-
A2494001). 
 
Anoikis assay 
For the anoikis assay, 6-well plates were coated with poly-HEMA (20mg/ml) (P3932; Sigma) 
dissolved in 96% ethanol. 5x105 Kras and A5+/-; Kras cells were seeded in triplicates and 
cultured for 48h in culture media. Surviving cells in the media were calculated using the 
neubauer counting chamber. 
 
Boyden Chamber Migration Assay 
1.5x105 Kras and A5+/-; Kras cells were seeded in triplicates in 6-well plates till confluence. 
100 µL serum free medium was added to upper chamber and 200 µL cells were added to 
chamber (2.5x105/mL in serum free medium). 750 µL full medium was added to lower 
chamber. Boyden-Chamber Assay plate was incubated at 37oC for 12-16 hours. After 
incubation, medium was removed from upper chamber and chambers were washed twice 
with PBS. Cells were fixed with formaldehyde (3.7% in PBS) for 2 minutes and washed with 
PBS twice. To permeabilize cells, 100% methanol was added to chambers for 20 minutes. 
After removing methanol chambers were washed twice with PBS. Chambers were place into 
wells and stained with Giemsa at room temperature for 15 minutes. After removing Giemsa 
solution, chambers were washed twice with PBS. Non-migrated cells were scraped off with 
cotton swabs from the membranes. Migrated cells were counted under a light microscope.  
 
Invasion assay 
6.5mm Transwell (#CLS3464; Sigma, Corning Costar, USA) with 8.0 µm Pore polyester 
membrane insert was used in 24-well culture plates. The upper surface of the membrane 
was coated with 100ml mixed matrigel (corning Life Sciences) per well. The matrigel was 
incubated at 37°C for gelling. 5x104 Kras and A5+/-; Kras cells were seeded in triplicates with 
200µl serum-free DMEM in the upper chamber. The lower chamber was filled with 750 µl of 
culture media. After 48h, the cells were fixed by formaldehyde 3.7% in PBS, permeabilized 
with 100% methanol and stained with crystal violet. Cells that invaded to the lower surface 
area of the membrane were calculated by counting stained cells. E64d (100 µM and E3132-
SIGMA) was used to inhibit cathepsin activity. Filopodia were quantified after 36h of seeding. 
 
Orthotopic Transplantation 
Littermates of A5+/-; Kras mice 8 weeks of age were injected orthotopically into the pancreas 
with 1×106 of either Kras or A5+/-; Kras tumor cell suspensions (resuspended in a solution of 
Matrigel (Corning 354234)/ DMEM without supplements in a ratio of 4/1) using a 26G needle. 
The mice were sacrificed 30 d after injection, or earlier when they reached sickness criteria. 
Pancreatic tissues were collected, embedded in paraffin and stained with haematoxylin and 
eosin (H&E). Lung, liver, lymph nodes, kidney, spleen, and duodenum were also collected 
and processed in the same way. Occurrence of tumors and metastasis was quantified and 
representative macroscopic and microscopic pictures were taken. 
 
Tail vein injection 
Littermates of A5+/-; Kras mice 8 weeks of age were injected intravenously through the tail 
vein with 1×106 of either Kras or A5+/-; Kras tumor cell suspensions (resuspended in 0,9% 
saline solution) using a 26G needle. The mice were sacrificed 20 d after injection, or earlier 
when they reached sickness criteria. The lungs were collected, embedded in paraffin and 
stained with haematoxylin and eosin (H&E). Mice were classified as metastasis positive or 
negative and representative macroscopic and microscopic pictures were taken. Body weight 
at time of sacrifice was measured to establish levels of cachexia. Metastatic tumor cells were 
re-isolated from pieces of lung tissue to determine cell morphology and survival capacity. 
 
Liposomal clodronate treatment 
For macrophage depletion in wildtype mice, clodronate-loaded liposomes (CP-010-010, 
Liposoma) were used. As control, mice were injected with control liposomes (PBS). For the 
experiment, mice were injected intraperitoneally (ml/ mouse) as follows:  
 
Prior to tail vein injection After tail vein injection 
Day -8 Day -4 Day 0 Day 4/ 8 Day 12/16 Day 20 
0.2 ml 0.2 ml 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
 
Clodronate and PBS treated mice were injected with A5+/-;Kras cells (biological duplicates) 
into the tail vein (at Day 0 according to the scheme above) to analyze the influence of 
macrophages on metastasis in the lung. Experiments were performed with at least 5 mice 
per group. Mice were sacrificed 21 days after tail vein injection due to sickness. Spleens of 
mice were analyzed after the experiments for F4/80 immunohistochemistry as described 
above. Lung metastasis was quantified as described below. 
 
Cytokine array 
In order to detect cellular cytokine profile supernatants of Kras and A5+/-; Kras cells were 
collected and processed as described above for immunoblotting. Lysates were then used 
according to the manufacturer’s instructions (Mouse Cytokine Array Panel A, Catalog 
Number ARY006, R&D Systems). Pixel intensity of individual plots was quantified using 
ImageJ software. The average of two spots corresponding to one cytokine was used to 
compare cytokine profile according to genotype. 
 
Macrophage differentiation assay 
To detect the effect of Kras and A5+/-; Kras cells on macrophage phenotype, Kras and A5+/-
;Kras cells were seeded in 6-well plates and cultivated for 48h. Supernatants were collected 
and applied on Raw macrophages (RAW 264.7 (ATCC® TIB-71™) cultivated in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10%FBS (#10082147; Gibco), 1% 
PenStrep (#1500-063; Gibco), 1%NEAA  (#11140050; Gibco). Macrophage phenotype was 
monitored and assessed by microscopy as described 6. 
For Arginase-1 Immunofluorescence macrophages were treated as described above and 
subsequently stained with anti-Arginase 1 (1/500) (610708 BD Transduction Laboratories). 
Briefly, unspecific binding was blocked with 5% serum at RT and cells were incubated over 
night at 4°C with the primary antibody. At the following day secondary antibody anti-mouse in 
goat Alexa Fluor 488 (1/300) (A-11001 Invitrogen) was applied for 1h at RT. In the end, 
slides were covered with DAPI containing mounting medium (H-1200 Vector Laboratories) 
and analyzed with fluorescence microscopy (Zeiss Axiovert 200M).  
 
Measurement of Ca2+ responses 
To measure Ca2+ responses, Kras and A5+/-;Kras cells were loaded with Fluo-4 by 
incubation with Fluo-4/AM (5μM) for 60min at room temperature (approximately 23oC) in Na-
Hepes-based solution (140mM NaCl, 4.7mM KCl, 1.13mM MgCl2, 10mM HEPES, 10mM 
Glucose, 1.8mM CaCl2, pH7.4). After that cells were washed by perfusion (gravity-based 
perfusion system) with the Na-Hepes-based solution and imaged every 2sec over a time 
period of 800sec using a Zeiss 510 confocal made  (excitation 488nm, emission LP505). 
Heat Inactivated FBS (0.01% or 0.05% diluted in the Na-Hepes-based solution) was applied 
when 200sec of recording were reached. 
Fluorescent responses (F) were normalized to fluorescence F0 recorded before the addition 
of FBS (average fluorescence value for measurements recorded during 190 - 200sec time 
interval). Amplitude of cytosolic Ca2+ responses was determined by the equation ((Fmax-
F0)/F0=DFmax/F0, with Fmax corresponding to the maximum Fluo-4 fluorescence measured 
during the 200-500sec interval. Amplitude of cytosolic Ca2+ responses of each single cell 
over 5min of FBS application was measured and the amplitudes were then averaged for 
each genotype (n > 170 cells for each genotype).  
Cells responding to FBS were defined as cells exciding 20% elevation threshold of 
normalized fluorescence (F/F0) in the first 5min of FBS application. 
 
Quantification of primary tumor and metastasis burden (iv and orthotopic TP; also 
with liposomal clodronate treatments) 
For quantification of primary tumor and metastasis burden (in all orthotopic transplantation 
and tail vein injection experiments) 2 mm-tissue slices were stained with H&E. Per H&E slide 
multiple pictures at 100x magnification were taken. Area (mm2) of tumor foci in pancreas and/ 
or lung tissues was calculated and expressed as % to all tissue area using a proprietary 
software package (Zeiss Axiovision, Oberkochen, Germany). Statistical analysis was done in 
between the genotypes (mean ± standard deviation (SD), Student t test). 
 
Quantification of F4/80-positive and CD206-positive macrophages 
For quantification of F4/80-positive macrophages in the lungs of tail vein-injected mice, tissue 
sections were stained for F4/80 via immunohistochemistry, as described above. Sections 
were subsequently photographed at 200x magnification. Number of positive cells was 
determined with Zeiss axiovision software. Sum from multiple photographs per tissue slide 
were generated and expressed in relation to the number of high power fields counted. 
Results were then averaged by genotype. 
F4/80-positive and CD206-positive macrophages were also quantified in the original tumors 
of Kras and A5+/-;Kras mice. For this, tissue slides were stained with the respective 
antibodies and the % of positive nuclei/ all nuclei were determined. 
 
Human sample analysis 
For ATG5 immunoblotting, a total of 67 human PDAC samples (Supplementary Table 2, 
Cohort 1) collected from the MTBIO tissue bank of the Institute of Pathology at the Technical 
University Munich, were analyzed as described above. Band density was quantified by using 
ImageJ and normalized to β-Actin. From these 67 patients, n=56 with known survival were 
grouped into ATG5 low-moderate expression (ATG5/ β-Actin ratio below 0,5) and high 
expression (ATG5/ β-Actin ratio equal/ above 0,5) and used for Kaplan-Meier survival 
analysis with GraphPad Prism.  
For ATG5 immunohistochemistry, two different cohorts (Cohort 2 and Cohort 3) were used. 
Cohort 2 consisted of 26 primary PDACs and their corresponding distant metastases that 
were resected between 2008 and 2013 at the University Hospital Heidelberg (Supplementary 
Table 3). The use of this tumor cohort for biomarker analysis has been approved by the 
ethics commission of the Klinikum rechts der Isar, Technische Universität München 
(403/17S). Primary tumor samples were used for ATG5 immunohistochemistry as described 
below for Cohort 3 and 19 of these were evaluated as described below for Cohort 3. In this 
analysis 4 patients from the Cohort 3 also exhibiting distant metastasis were included as 
well. The percentages of patients with distant metastasis in the low-moderate and in the high 
ATG5-expressing groups were calculated as described below for Cohort 3. 
Cohort 3 consisted of a patient cohort with primary resected PDACs. The cohort was 
investigated previously in several studies 7-9 and included 200 individuals (Supplementary 
Table 4) that received partial pancreatoduodenectomy for PDAC between 1991 and 2006 at 
the Charité University Hospital Berlin. The use of this tumor cohort for biomarker analysis 
has been approved by the Charité University ethics committee (EA1/06/2004). 
Tissue microarrays of both IHC cohorts were generated as previously described 7, 10. In detail 
three tumor cores (diameter 1.5 mm) of representative tumor areas selected by a board 
certified pathologist on H&E stained slides were punched out of formalin-fixed paraffin 
embedded (FFPE) tissue blocks and arranged in a newly generated paraffin block. TMAs 
were made using a tissue microarrayer (Beecher Instruments, Sun Praierie, USA). Staging of 
both cohorts followed the WHO recommendations at the time of cohort generation (TNM-
classification of the 7th edition). Clinical and demographic information was obtained from the 
respective institutional patient databases, by reviewing medical charts and pathological 
reports. Patient follow-up data were obtained from clinical records and via direct contact with 
patients and/ or their relatives. For Immunohistochemistry, 2µm sections prepared with a 
rotary microtome (HM355S, ThermoFisher Scientific, Waltham, USA) were collected from 
134 patients in this cohort (Supplementary Table 3). Immunohistochemistry was performed 
using a Bond RXm system (Leica, Wetzlar, Germany, all reagents from Leica) with a primary 
antibody against ATG5 (NB110-53818 Novus Biologicals). Briefly, slides were deparaffinized 
using deparaffinization solution, pretreated with Epitope retrieval solution 1 (corresponding to 
citrate buffer pH 6) for 20 minutes. Antibody binding was detected with a polymer refine 
detection kit without post primary reagent and visualized with DAB as a dark brown 
precipitate. Counterstaining was done with hematoxyline. The membranous ATG5 was 
scored according to the percentage and intensity of positive cells on a 0 to 3+ scale 
(negative as score 0, faint expression as score 1+, moderate expression as score 2+ and 
strong expression as score 3+; see Figure 7B for a panel of staining). Kaplan-Meier survival 
analysis was performed by GraphPad Prism with a total of 79 patients from the 134. Patients 
with no available survival and patients with no death follow up were removed from the 
analysis. The two groups in the Kaplan-Meier analysis included low-moderate ATG5-
expressing patients (with scores 1 and 2) and high ATG5-expressing patients (score 3). 
Lymph node status and resection status in these patients was expressed as % patients 
referring to the total patients belonging to the two groups. 
 
An overview of the three different cohorts used can be found in the following table: 
 
Cohort 
number 
Status Site Analysis Number of 
patients 
1 Postoperative Primary Western blot 56 
2 Palliative/ 
metastatic 
Primary IHC 23 
3 Postoperative Primary IHC 79 
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Supplementary Figure 1: Relating to Figure 1. 
(A) GFP-LC3 and CK19 immunofluorescence of A5;Kras mice expressing transgenic GFP-
LC3; white arrowhead indicates diffuse GFP-LC3 staining; nuclei are detected with DAPI. (B) 
Macroscopic and microscopic appearance of pancreata from 18-week old Atg5 deficient 
(A5;Kras) and Atg5 heterozygous mice (A5+/-;Kras) compared to 18-week old Atg5 proficient 
mice (Kras); oncogenic Kras is expressed in all groups of mice. (C) Pancreas/Body weight 
ratio in 4-/9-/18/ and more than 18-week old Kras, A5+/-;Kras, and A5;Kras mice (n≥3). (D) 
Quantification of Acinar-to-Ductal Metaplasia (ADM) per High Power Field (HPF) in 4-week 
old Kras, A5+/-;Kras, A5;Kras mice (n≥4). (E) Quantification of PanIN-1/-2/-3 per High Power 
Field (HPF) in 9-/ 18-week old Kras, A5+/-;Kras, and A5;Kras mice (n≥3). (F) Kaplan-Meier 
survival curve of Kras (n=54), A5+/-;Kras (n=13), and A5;Kras (n=24) mice (Median survival 
475, 451, 184 days respectively; ***P<0.0001 comparing Kras and A5;Kras). Mean±SD, 
*P<0.05, **P<0.01, ***P<0.001. Scale bars equal 50μm. 
 
  
Supplementary Figure 2: Relating to Figure 2. 
Colony formation assays in Kras and A5+/-;Kras cells after (A) 10% FCS cultivation, (B) 6-AA 
(6-Aminonicotinamide), (C) Rotenone, (D) Galactose/ Glutamine, and (E) high glucose 
treatment. Graphs are shown on the left, representative pictures on the right. Mean±SD 
(n=3). 
 
  
Supplementary Figure 3: Relating to Figure 3. 
(A) Representative macroscopic and microscopic pictures of pancreatic tumors from wildtype 
mice after orthotopic transplantation (TP) of Kras and A5+/-;Kras cells; primary tumors are 
shown on the top, tumors formed after transplantation in the fourth picture from the top, and 
CK19 immunohistochemistry on the bottom; Quantification of primary pancreatic tumor 
burden in mice after orthotopic transplantation of Kras and A5;Kras cell lines (% area of 
tumor tissue, n>3) (bottom). (B) Representative macroscopic and microscopic pictures of 
metastasis (lung, LN=lymph node, spleen) after TP of A5+/-;Kras cells into wildtype mice; 
white arrowheads indicate metastasis (top); metastasis incidence (%) after TP of Kras and 
A5+/-;Kras cells (n≥5) (bottom). (C) Representative macroscopic picture of wildtype mice 
after tail vein (i.v.) injection of Kras and A5+/-;Kras cells (left), and quantification of body 
weight in male and females (n≥3) (right). (D) H&E picture of liver and spleen metastasis after 
i.v. of A5+/-;Kras cells; asterisks indicate metastasis (top); representative bright field pictures 
of Kras and A5+/-;Kras cells isolated from the lung of wildtype mice after i.v.; asterisk and 
circle indicate two different cell populations (bottom). (E) Colony formation assay in Kras, 
A5+/-;Kras, and Kras cells after 58, 94% knockdown (KD) of Atg5 (n>3) (left); representative 
pictures are shown (right); cells were cultivated in medium with 10% FCS. Mean±SD, 
*P<0.05. Scale bars equal 50μm. 
  
Supplementary Figure 4: Relating to Figure 4. 
(A) Classification of significantly enriched gene sets into categories, based on Transcription 
Factor Binding Motif database for Kras (left) and A5+/-;Kras (right) cells; pie charts show 
classification and tables highlight examples of enriched pathways (NES≥1.0, P<0.05; P value 
0.0 indicates P<0.001). (B) GSEA diagrams of significantly enriched KEGG pathways found 
in Kras (top) and A5+/-;Kras (bottom) cells. (C) Heat map of most highly regulated genes 
identified by GSEA in Kras and A5+/-;Kras cells. 
 
  
Supplementary Figure 5: Relating to Figure 5. 
(A) Analysis of phospho-AMPKa, AMPKa, phospho-S6, mitochondrial complexes (COX I, 
COX II/IV, ATP Core 2), SOD2, and BiP in protein lysates and Xbp1 splicing 
(Xbp1u=unspliced, Xbp1s=spliced) in RNA-preparations from Kras and A5+/-;Kras cells; β-
Actin and cyclophilin were used as loading controls. (B) Coupling efficiency (%) of 
mitochondria in Kras and A5+/-;Kras cells as measured by seahorse (n≥30). (C) qRT-PCR of 
Sod1 and Nrf2 in mRNA extracts from Kras and A5+/-;Kras cells; data are normalized to 
cyclophilin (n=3). Mean±SD. 
 
  
Supplementary Figure 6: Relating to Figure 6. 
(A) Proportions of Kras and A5+/-;Kras cells producing Ca2+ responses after stimulation with 
0.01% or 0.05% FBS (n>170). (B) Cathepsin B (CTSB) extracellular activity (% extracellular 
activity versus total activity) as measured from supernatants of Kras and A5+/-;Kras cells 
(n=15). (C) Western blot analysis of Pro-cathepsin B (Pro-CTSB), Pro-cathepsin D (CTSD), 
and Pro-cathepsin L (Pro-CTSL) in supernatants of Kras and A5+/-;Kras cells. (D) Colony 
formation assay in Kras and A5+/-;Kras cells after cultivation with E64d. (E) Illustration of 
lysosome-associated DNA copy number gain (red) or loss (blue) (TCGA data) in normal 
pancreas versus pancreatic ductal adenocarcinoma (PDAC) samples (log2 copy number 
units). Mean±SD. 
 
  
Supplementary Figure 7: Monoallelic loss of Atg5 induces pro-tumorigenic 
inflammation. 
(A) Cytokine profile expression shown by immunoblotting of protein lysates from Kras and 
A5+/-;Kras supernatants (left); quantification of average pixel intensity between two dots 
corresponding to the same cytokine; numbers above graph correspond to dot-position in plot 
(n=1). (B) Quantification of M1 and M2 macrophages (% of all macrophages) according to 
their morphology after stimulation with supernatants from Kras and A5+/-;Kras cells (n≥3); 
representative bright field pictures are shown indicating morphology of undifferentiated 
(asterisk), M1 (white arrowhead), and M2 (black arrowhead) macrophages (left); Arginase-1 
immunofluorescence in macrophages after stimulation with supernatants from Kras and 
A5+/-;Kras cells; nuclei are detected with DAPI (right). (C) Representative 
immunohistochemistry pictures of F4/80 and CD206 in primary tumors from Kras and A5+/-
;Kras mice (top); quantification of F4/80 and CD206-positive macrophages (% positive 
nuclei) in Kras and A5+/-;Kras primary tumors (n>3). (D) Immunohistochemical quantification 
of F4/80-positive cells per high power field (HPF) in the lungs of mice after i.v. with Kras and 
A5+/-;Kras cells (n=20) (left); representative F4/80 and Arginase 1 (Arg1) 
immunohistochemistry in tissue sections from the lungs of mice after tail vein injection (i.v.) 
with Kras and A5+/-;Kras cells; black arrowheads indicate F4/80-positive macrophages 
(right). (E) Quantification of lung metastasis (% area) after tail vein injection of A5+/-;Kras 
cells into PBS or clodronate-treated wildtype mice (n>3) (left); representative H&E pictures of 
the lung and F4/80 immunohistochemistry pictures of the spleen after the respective 
treatments. Mean±SD, *P<0.05, **P<0.01, ***P<0.001. Scale bars equal 50μm. 
 
  
Supplementary Table 1: PDAC and Metastasis in A5+/-;Kras mice 
List of A5+/-;Kras mice that were used for Pancreatic Adenocarcinoma (PDAC) and 
metastasis quantification; mouse number (ID), Gender, Age (days), PDAC incidence, 
Histology, liver/ lung/ diaphragm metastasis, ascites incidence, and other abnormalities are 
presented; Male=M, Female=F, Yes=Y, No=N, Ductal=D, Undifferentiated=U, lymph node 
infiltration=LN, Spleen infiltration=Spl, Kidney infiltration=Kd 
 
  
ID Gender Age PDAC Histology Liver Lung Diaphragm Ascites Others 
7135 F 698 Y D N N N N  
9138 F 293 Y D Y N N N LN 
9137 F 340 Y D Y Y Y Y LN 
9384 F 453 Y D Y Y Y Y Spl 
2835 M 389 Y U N N N N  
M5683 M 133 N N N N N N  
M5681 M 346 Y D Y Y Y Y LN 
M5617 F 385 Y D N Y N N  
M5618 M 451 Y D N Y Y N  
M5551 M 578 Y D Y Y N Y LN 
P642 M 673 Y D Y N Y Y LN/Spl/Kd 
M6215 F 451 N N N N N N  
Supplementary Table 2: Human pancreatic cancer patient cohort (postoperative, 
Cohort 1). 
List of the analyzed human pancreatic cancer samples for ATG5-western blot (n=67), 
collected from the MTBIO tissue bank of the Institute of Pathology at the Technical University 
Munich. Histology (Pancreatic Ductal Adenocarcinoma (PDAC)), extent of primary tumor (T), 
lymph node infiltration (N), metastasis (M), tumor differentiation grade (G), survival (months), 
ATG5 protein expression normalized to b-Actin and quantified by ImageJ (ATG5), and Tumor 
stage are shown. Samples marked with red or containing an X were not used in the analysis. 
The last 4 samples did not have patient data and were excluded from the study. 
 
Histology T N M G Survival ATG5 Stage 
PDAC 4 1 1 3 13 1.035 IV 
PDAC 3 1 1 3 12 0.304 IV 
PDAC 3 1 1 3 9 0.460 IV 
PDAC 3 1 1 3 11 0.030 IV 
PDAC 3 1 1 2 7 0.000 IV 
PDAC 4 1 0 3 9 0.472 III 
PDAC 4 1 0 3 12 0.144 III 
PDAC 4 1 x 2 17 0.369 III 
PDAC 4 1 x 2 5 0.294 III 
PDAC 3 1 0 4 13 0.529 III 
PDAC 3 1 0 3 26 0.624 IIB 
PDAC 3 1 x 3 10 0.554 IIB 
PDAC 3 1 x 3 29 0.685 IIB 
PDAC 3 1 x 3 29 0.698 IIB 
PDAC 3 1 0 3 7 0.873 IIB 
PDAC 3 1 0 3 4 0.769 IIB 
PDAC 3 1 0 3 5 0.016 IIB 
PDAC 3 1 0 3 3 0.488 IIB 
PDAC 3 1 0 3 lost to FU 0.621 IIB 
PDAC 3 1 0 3 10 0.491 IIB 
PDAC 3 1 0 3 4 0.526 IIB 
PDAC 3 1 0 3 14 1.308 IIB 
PDAC 3 1 0 3 9 0.966 IIB 
PDAC 3 1 0 3 17 1.005 IIB 
PDAC 3 1 0 3 11 0.428 IIB 
PDAC 3 1 0 3 lost to FU 0.838 IIB 
PDAC 3 1 0 3 lost to FU 0.042 IIB 
PDAC 3 1 0 2 3 0.380 IIB 
PDAC 3 1 0 2 29 0.382 IIB 
PDAC 3 1 0 2 25 0.350 IIB 
PDAC 3 1 0 2 34 0.649 IIB 
PDAC 3 1 0 2 46 0.548 IIB 
PDAC 3 1 0 2 31 0.758 IIB 
PDAC 3 1 0 2 lost to FU 0.167 IIB 
PDAC 3 1 0 2 10 0.115 IIB 
PDAC 3 1 0 2 40 0.157 IIB 
PDAC 3 1 0 2 3 0.964 IIB 
PDAC 3 1 x 2 13 0.258 IIB 
PDAC 3 1 x 2 10 0.255 IIB 
PDAC 3 1 0 1 24 0.777 IIB 
PDAC 3 1 0 1 56 0.210 IIB 
PDAC 3 1 X 
 
14 0.535 IIB 
PDAC 2 1 0 1 23 0.101 IIB 
PDAC 1 1 0 3 60 0.047 IIB 
PDAC 3 0 0 3 4 0.805 IIA 
PDAC 3 0 0 3 31 0.461 IIA 
PDAC 3 0 x 3 18 0.486 IIA 
PDAC 3 0 x 3 8 0.539 IIA 
PDAC 3 0 0 3 76 2.504 IIA 
PDAC 3 0 0 3 10 0.653 IIA 
PDAC 3 0 0 3 lost to FU 0.502 IIA 
PDAC 3 0 0 2 32 0.911 IIA 
PDAC 3 0 x 2 21 0.303 IIA 
PDAC 3 0 0 2 10 0.052 IIA 
PDAC 3 0 x 2 39 0.388 IIA 
PDAC 3 0 0 2 36 0.298 IIA 
PDAC 3 0 0 2 30 1.674 IIA 
PDAC 3 0 0 2 18 0.572 IIA 
PDAC 3 0 0 2 lost to FU 0.405 IIA 
PDAC 3 0 x 1 23 0.747 IIA 
PDAC 3 0 x 1 34 0.181 IIA 
PDAC 2 0 0 3 lost to FU 0.533 IB 
PDAC 2 0 0 2 23 0.098 IB 
PDAC 
     
0.848 
 PDAC 
     
0.006 
 PDAC 
     
0.312 
 PDAC 
     
0.493 
  
 
Supplementary Table 3: Human pancreatic cancer patient cohort (palliative/ 
metastatic, Cohort 2). 
List of the analyzed human pancreatic cancer samples for ATG5-immunohistochemistry 
(n=26). Each row represents one individual diagnosed with PDAC (Pancreatic Ductal 
Adenocarcinoma, as mentioned beneath the headline Histology) and exhibiting distant 
metastasis (M1, i.e., HEP=hepatic, PER=peritoneal, SKI=skin, ADR=adrenal). Patients were 
resected between 2008 and 2013 at the University Hospital Heidelberg. ATG5 protein was 
detected by immunohistochemistry; membranous ATG5 was scored according to the 
percentage and intensity of positive cells on a 0 to 3+ scale (negative as score 0, faint 
expression as score 1+, moderate expression as score 2+ and strong expression as score 
3+). The sum score is provided in the second column. Patients without ATG5 score were 
excluded from the analysis. 
 
Histology ATG5 M1  
PDAC 2.3 HEP, PER 
PDAC 3 HEP 
PDAC 
 
HEP 
PDAC 2.8 HEP 
PDAC 1 HEP 
PDAC 
 
HEP, PER, ADR 
PDAC 
 
HEP 
PDAC 2.9 HEP 
PDAC 
 
HEP 
PDAC 2 PER 
PDAC 2 PER 
PDAC 2.8 PER 
PDAC 3 HEP 
PDAC 2.1 HEP 
PDAC 1.8 HEP 
PDAC 2.5 HEP 
PDAC 2 SKI 
PDAC 2.9 HEP 
PDAC 1.9 HEP 
PDAC 
 
HEP 
PDAC 
 
HEP 
PDAC 3 HEP 
PDAC 2.1 HEP 
PDAC 
 
SKI 
PDAC 3 HEP 
PDAC 3 HEP 
 
 
Supplementary Table 4: Human pancreatic cancer patient cohort (postoperative, 
Cohort 3). 
List of the analyzed human pancreatic cancer samples for ATG5-immunohistochemistry 
(n=134). Each row represents one individual diagnosed with PDAC (Pancreatic Ductal 
Adenocarcinoma) at the Charité University Hospital Berlin. Event of death (yes=1, no=0), 
Survival (days), lymph node status (pN), metastasis status (pM), tumor stage (pT), patient 
characteristics (gender, age), UICC tumor staging, and resection margin (R) are shown. 
ATG5 protein was detected by immunohistochemistry; membranous ATG5 was scored 
according to the percentage and intensity of positive cells on a 0 to 3+ scale (negative as 
score 0, faint expression as score 1+, moderate expression as score 2+ and strong 
expression as score 3+). The sum score is provided in the first column. Patients without 
death event and no registered survival were removed from the analysis. 
 
ATG5 Death Survival pN pM pT Gender Age Stage R 
2.7 1 431 0 0 2 w 74 Stage I 0 
2 1 898 1 0 2 w 75 Stage IIB 0 
1 0 
 
0 0 3 w 64 Stage IIA 0 
2.7 0 5748 1 0 3 w 56 Stage IIB 1 
3 1 278 1 0 3 m 47 Stage IIB 0 
1 1 780 1 0 2 m 67 Stage IIB 0 
3 1 407 1 0 3 w 62 Stage IIB 0 
2.4 1 452 1 1 3 m 31 Stage IV 1 
3 1 1166 1 0 2 w 63 Stage IIB 0 
2.5 1 215 0 0 2 w 58 Stage I 0 
3 1 629 1 0 2 m 53 Stage IIB 1 
2.8 1 329 1 0 3 w 62 Stage IIB 0 
2.8 1 46 0 0 2 w 61 Stage I 0 
2.9 1 406 1 0 3 m 69 Stage IIB 0 
2.1 1 236 0 0 2 w 70 Stage I 1 
2.6 0 2459 0 0 2 w 71 Stage I 
 2.6 
  
1 0 2 m 64 Stage IIB 0 
2.2 1 862 1 0 2 w 64 Stage IIB 0 
2.3 1 448 1 0 2 m 71 Stage IIB 0 
2.5 0 2302 1 0 2 m 64 Stage IIB 
 3 1 287 1 0 3 w 47 Stage IIB 1 
3 0 305 1 0 3 m 62 Stage IIB 
 1.3 1 945 1 0 3 w 75 Stage IIB 0 
2.2 1 832 1 0 3 w 62 Stage IIB 0 
2.9 1 685 0 0 3 w 59 Stage IIA 
 1.2 
  
1 0 3 m 50 Stage IIB 0 
2 1 
 
1 0 2 m 60 Stage IIB 
 1.3 0 2049 0 0 3 m 63 Stage IIA 0 
2.2 
  
1 0 3 m 66 Stage IIB 0 
2.9 1 1045 1 0 3 w 49 Stage IIB 0 
2.9 0 2104 0 0 2 w 64 Stage I 0 
3 1 1743 1 0 2 m 71 Stage IIB 0 
2.2 
  
1 0 3 w 59 Stage IIB 0 
1.2 0 
 
0 0 3 m 59 Stage IIA 0 
2.9 1 744 1 0 3 w 73 Stage IIB 1 
3 1 740 1 0 3 m 50 Stage IIB 0 
3 1 1258 0 0 3 w 62 Stage IIA 0 
2.5 1 809 1 0 3 w 61 Stage IIB 0 
3 1 167 1 0 3 m 66 Stage IIB 0 
2 1 348 1 0 3 w 59 Stage IIB 1 
2.2 1 911 1 0 3 m 64 Stage IIB 0 
2.5 1 779 0 0 3 w 69 Stage IIA 0 
2.9 1 471 0 0 2 w 76 Stage I 0 
2.3 1 125 1 0 3 m 63 Stage IIB 0 
2.2 0 1427 0 0 3 m 65 Stage IIA 1 
3 1 395 0 0 3 m 60 Stage IIA 0 
1.2 1 
 
1 0 2 w 77 Stage IIB 
 3 1 
 
1 0 3 m 38 Stage IIB 
 2 1 
 
1 0 3 w 76 Stage IIB 1 
3 0 
 
1 0 3 m 63 Stage IIB 1 
3 
  
1 0 3 w 65 Stage IIB 0 
2.6 1 432 0 0 2 w 69 Stage I 0 
2.7 1 805 1 0 3 m 
 
Stage IIB 
 2.2 0 2644 0 0 3 w 62 Stage IIA 
 3 1 496 1 0 3 w 79 Stage IIB 
 2.8 1 198 1 0 3 m 49 Stage IIB 0 
3 1 
 
1 0 3 m 70 Stage IIB 
 3 1 404 1 0 3 m 73 Stage IIB 
 2.8 1 
 
0 0 3 w 77 Stage IIA 
 2 1 902 1 0 3 w 73 Stage IIB 
 2.8 1 112 1 1 3 m 55 Stage IV 0 
3 1 715 1 0 3 m 64 Stage IIB 0 
3 1 209 1 0 3 w 51 Stage IIB 0 
2.8 1 260 1 0 3 m 51 Stage IIB 0 
3 1 353 1 0 3 w 67 Stage IIB 0 
3 0 
 
1 0 3 m 48 Stage IIB 
 1.8 1 611 1 0 3 w 78 Stage IIB 0 
2.9 1 98 1 0 3 w 63 Stage IIB 0 
2.7 1 28 0 0 3 w 74 Stage IIA 1 
2.7 0 2645 1 0 2 m 53 Stage IIB 0 
2 0 
 
0 0 2 w 59 Stage I 0 
3 0 2609 1 0 3 m 69 Stage IIB 0 
2.8 1 
 
1 0 3 m 72 Stage IIB 0 
2.8 1 255 1 0 3 m 74 Stage IIB 0 
3 1 
 
0 0 3 m 78 Stage IIA 0 
2.9 1 184 0 0 4 w 72 Stage III 0 
3 1 291 1 0 3 w 69 Stage IIB 0 
3 0 1273 0 0 3 m 56 Stage IIA 0 
3 1 1183 0 0 3 m 50 Stage IIA 0 
2.6 1 96 1 0 3 w 75 Stage IIB 1 
3 1 
 
1 0 3 m 57 Stage IIB 0 
0.7 1 
 
1 0 4 w 70 Stage III 0 
3 1 1064 1 0 3 m 72 Stage IIB 1 
2 1 288 1 0 3 w 61 Stage IIB 0 
2.8 1 192 1 0 4 m 57 Stage III 1 
2.8 1 370 1 0 3 w 74 Stage IIB 0 
2.9 1 1186 1 0 3 w 72 Stage IIB 0 
3 1 394 0 0 3 m 69 Stage IIA 1 
3 0 17 1 0 3 w 68 Stage IIB 1 
1 1 369 0 0 3 w 79 Stage IIA 1 
2.8 
  
1 0 3 w 62 Stage IIB 1 
2.8 0 7 1 0 3 m 60 Stage IIB 1 
3 1 59 1 0 3 w 61 Stage IIB 1 
3 1 289 1 0 4 m 60 Stage III 1 
3 
  
1 0 3 m 70 Stage IIB 0 
2.2 
  
0 0 1 m 66 Stage I 0 
3 1 222 1 0 3 m 61 Stage IIB 1 
2.05 0 415 0 0 3 w 81 Stage IIA 0 
3 1 653 1 1 3 w 46 Stage IV 0 
2 1 12 1 0 4 m 69 Stage III 1 
3 
  
1 0 3 m 59 Stage IIB 1 
2.8 0 12 1 0 3 m 67 Stage IIB 0 
2.8 1 205 1 0 3 m 69 Stage IIB 1 
3 
  
1 0 4 m 73 Stage III 0 
2.5 1 615 1 0 3 m 54 Stage IIB 1 
2.3 1 263 1 0 3 m 67 Stage IIB 1 
2.7 
  
0 0 3 m 65 Stage IIA 0 
2 1 915 0 0 3 m 68 Stage IIA 0 
3 
  
1 0 3 m 75 Stage IIB 0 
2 1 316 1 0 3 m 64 Stage IIB 0 
3 1 
 
1 0 2 m 73 Stage IIB 0 
1.8 0 1079 1 0 3 w 59 Stage IIB 0 
3 1 455 1 0 3 m 56 Stage IIB 0 
2.7 0 210 1 0 3 m 43 Stage IIB 1 
1.2 1 603 1 0 3 w 58 Stage IIB 1 
2.8 0 865 1 0 3 w 57 Stage IIB 0 
2.3 
  
1 0 3 m 77 Stage IIB 1 
3 0 311 1 0 3 m 61 Stage IIB 0 
2.3 1 199 1 1 3 m 41 Stage IV 0 
2.9 0 866 0 0 3 m 75 Stage IIA 0 
2.2 1 582 1 0 3 m 75 Stage IIB 0 
2.1 
  
1 0 3 w 75 Stage IIB 1 
2.3 1 265 1 0 4 m 74 Stage III 1 
2 0 696 1 0 3 w 66 Stage IIB 0 
2.2 1 185 1 0 3 m 51 Stage IIB 1 
2.1 1 268 1 0 3 w 81 Stage IIB 0 
2.9 0 586 0 0 3 m 69 Stage IIA 0 
1.5 0 5 0 0 3 w 69 Stage IIA 0 
2.2 1 1104 1 0 3 w 68 Stage IIB 0 
2.6 1 324 1 0 3 w 68 Stage IIB 1 
2.2 1 380 1 0 3 m 58 Stage IIB 0 
2.3 1 249 1 0 3 w 63 Stage IIB 0 
2.3 1 166 1 0 3 m 72 Stage IIB 0 
2.8 1 216 1 0 3 m 55 Stage IIB 1 
 
SUPPLEMENTARY MATERIALS AND METHODS: 
 
Quantification of relative pancreatic weight, tumor incidence, and metastasis 
incidence 
Kras, A5+/-; Kras, and A5; Kras mice were sacrificed at 4, 9, and 18 weeks of age or at the 
time point of sickness. Relative pancreatic weight was calculated from the pancreas and 
body weight obtained during sacrifice (pancreas weight/ body weight). Tumor incidence and 
metastasis incidence (% of tumor or metastasis-positive mice relative to all mice sacrificed) 
was calculated after histological examination. Metastasis-positive mice were mice with 
metastasis in liver, lung, or diaphragm from the pool of pancreatic tumor-positive mice. 
Ascites, lymph node, spleen, or kidney infiltration was also evaluated (see Supplementary 
Table 1). 
 
Detection of GFP-LC3 puncta 
GFP-LC3 mice with or without concomitant Kras expression were sacrificed after standard 
fed conditions. Pancreas was snap frozen in freezing medium (Tissue-Tek O.C.T. 
Compound, Weckert Labortechnik, Germany) and 7-10mm thick cryo-sections were mounted 
on adhesive-coated slides. Sections were air dried, fixed in 100% ethanol for 8 minutes at 
RT, washed with PBS and covered with DAPI containing mounting medium (H-1200 Vector 
Laboratories, CA). Sections were processed and kept in the dark until analysis. Puncta 
formation was detected by analysis of green fluorescence (EX/EM 470/525nm) with 
fluorescence microscopy (Zeiss Axiovert 200M).  
 
Tumor cell isolation and cultivation 
Primary pancreatic tumor cell lines were established from isolated murine pancreatic tumors. 
To establish the cell lines, pieces of pancreatic tumor tissue from Kras, A5+/-; Kras, and A5; 
Kras mice were placed in full culture medium (see below) and tumor cells were allowed to 
grow out of the tissue. Cell lines were routinely cultured under standard conditions (5% CO2, 
37 C) in culture media (Dulbecco’s modified Eagle medium (DMEM) supplemented with 
10%FBS (#10082147; Gibco), 1% PenStrep (#1500-063; Gibco), 1% Non-Essential-Amino-
Acids (NEAA #11140050; Gibco)). On average, cells were passaged 5 times prior to any 
experiments. 
 
Knockdown of mAtg5 
Experimental procedures were followed as described previously 1. Briefly: 
 
Transfection of 293T cells for production of lentiviral particles 
??????????????????? ??????????????????????????????????????????????????????????????? ?????????????????????????????????
5 x 106 293T cells were seeded in 10 cm dishes. After one day, media was replaced and co-
transfection of transfer plasmids purchased from Sigma Aldrich (TRCN0000327456 (54% 
knockdown, validated), TRCN0000327358 (58% knockdown, validated), TRCN0000363558 
(81% knockdown, validated), TRCN0000375754 (86% knockdown, validated), and 
TRCN0000099432 (94% knockdown, validated)) with lentiviral packaging plasmids 
(pMD.GP, pRSV-rev, pMD.G) was performed using lipofectamine 2000 (Thermo Fisher 
Scientific). shRNA that does not target any known human or mouse gene (shNT) was used 
as a control. Two days later, lentiviral particles were harvested from the supernatant and 
frozen at -80°C. 
 
Transduction of target cells with mATG5 knockdown constructs 
Target Kras cells were seeded in 6 cm dishes. One day later, media was aspirated and 1 ml 
of lentiviral suspension was added to cells in presence of 8 µg/ml Polybrene (Sigma Aldrich). 
After 2 h at 37°C, 4 ml media was added. Selection of transduced cells was performed using 
10 µg/ml puromycin.  
 
Experimental analysis 
Cells were tested in western blotting for Atg5, LC3, and β-Actin expression (as described 
below) and the knockdown percentage was confirmed. Cells with 54%, 58%, 81%, 86%, and 
94% mAtg5-knockdown were further used in colony formation (full medium, 10% FCS), 
Boyden Chamber migration, invasion, and tail vein injection experiments as described below. 
Experiments were performed in triplicates. 
 
In vitro cathepsin activity measurements 
Activities of cathepsins B, L, and D were intra- and extracellularly assessed in cell lysates 
and culture media of primary pancreatic tumor cell lines. Tumor cells were separated from 
culture media by centrifugation at 1000 g for 10 min. Then, cell pellet and culture medium 
were snap frozen. After thawing tumor cells were subsequently resuspended in ice-cold 
homogenization buffer (5 mM MOPS pH 6.5, 250 mM sucrose, 1 mM Mg2SO4, 0.13% Triton 
X100l) and lysed by sonication. Cathepsin B and -L were determined as Ca074- and N1760- 
sensitive activity in assay buffer (50 mM sodium phosphate buffer [pH 5.5], 1 mM EDTA, and 
1 mM dithiothreitol) using the fluorogenic substrates Z-Arg-Arg-7-amino-4-methylcoumarin A 
(10µM, #31213-v, Pepta Nova) and Z-Phe-Arg-7-amino-4-methylcoumarin (10µM, #3095-v, 
Pepta Nova), respectively. Cathepsin D activity was measured in 50 mM sodium acetate 
buffer pH 4.0 using the fluorogenic substrate Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-
Lys(Dnp)-D-Arg-NH2 (10µM, #3200-v, Pepta Nova). The release of 7-amido-4-
methylcoumarin was kinetically monitored over 10 minutes at the excitation/emission 
wavelength of 360/438 nm in a Safire microplate reader (Tecan, Grödig, Austria) by 
spectrofluorometry. Intra- and extracellular portions of cathepsin activities were normalized to 
the protein concentration in cell lysates determined by BioRad protein Assay kit. 
 
Subcellular fractionation by isopycnic Percoll density centrifugation and 
measurement of GLDH activity 
To analyze distribution and integrity of mitochondria in subcellular fractions pelleted tumor 
cells harvested from primary pancreatic tumor cells lines (produced as described above) 
were resuspended in HS buffer (250mM sucrose, 10 mM citric acid, 0.5 mM EGTA, 0.1 mM 
MgSO4 [pH 6.0]) and homogenized by 5 strokes using a Dounce homogenizer. After 
centrifugation at 100g post-nuclear supernatant was applied onto an isotonic 50% (v/v) 
Percoll/HS buffer solution (described above) at pH 7.27 and subsequently separated by 
isopycnic centrifugation at 50,000 g for 45 min at 4°C. After separation the percoll gradient 
was portioned in 46 fractions using a peristaltic pump beginning from the bottom and 
fractions were stored at -80°C until further use.  
Activity of GLDH as a marker of mitochondrial distribution in subcellular fractions was 
determined spectrophotometrically at 340 nm according to NADH2 oxidation with 2-
oxoglutarate and NH4+ as a substrate by the method of E. Schmidt 2. 
 
Immunoblotting 
For immunoblotting, Kras, A5+/-; Kras, and A5; Kras cells were pelleted and snap frozen. 
Cell pellets were resuspended in ice cold protein lysis buffer (50mM HEPES pH 7.9, 150mM 
NaCl, 1mM EDTA pH 8.0, 0.5% NP-40 (Roche), 10% Glycerol) supplemented with 
protease/phosphatase inhibitors (SERVA), sonicated, and kept on ice. Extracellular proteins 
secreted into the culture medium were concentrated by trichloroacetic acid precipitation 
(TCA, final concentration 6 %) in the presence of 2% Na-deoxycholate by the method A. 
Bensadoun3. Concentration was determined by BioRad protein Assay kit and concentration 
Laemmli 
buffer (300 mM Tris-HCl, pH 6.8, 10% (w/v) SDS, 50% (v/v) Glycerol, 0.05% (w/v) 
Bromphenole blue, 5% (v/v) β-mercaptoethanol) except when used for detection of 
mitochondrial oxidative phosphorylation complexes. Protein lysates were separated by SDS-
gel electrophoresis and transferred to PVDF membranes. Following over night incubation 
with primary antibody at 4°C, proteins were detected using horseradish peroxidase-
conjugated secondary antibodies anti-mouse (NA931V GE Healthcare Life Sciences), anti-
rabbit (NA934V GE Healthcare Life Sciences) or anti-guinea pig (A7289 Sigma) and ECL 
reagent (Amersham). The primary antibodies used include: Anti-Atg5 (1/1000) (NB110-
53818 Novus Biologicals), anti-p62 (1/1000) (GP62-C Progen), anti-LC3 (1/1000) (PD014 
MBL International), anti-Cathepsin B (1/5000) (AF965, R&D Systems), anti-p53 (1/500) 
(NCL-p53-CM5p Novocastra), anti-Cathepsin L (1/5000) (AF1515, R&D Systems) anti-
Cathepsin D (1/5000) (cs-10725, Santa Cruz Biotechnology), anti-phospho-AMPKa (1/1000) 
(2535 Cell Signaling Technology), anti-AMPKa (1/1000) (2532 Cell Signaling Technology), 
anti-phospho-S6 (1/1000) (2211 Cell Signaling Technology, anti-SOD2 (1/1000) (ADI-SOD-
111 Enzo), anti-BiP (1/1000) (AB21685 Abcam), anti-MitoProfile Total OXPHOS Rodent 
Western Blot antibody cocktail (1/1000) (MS604 Mitosciences), -β-Actin (1: 2000) 
(A5441, Sigma). 
 
Histochemistry and immunohistochemistry 
For proliferation analysis mice were labeled with 50mg of BrdU (B5002 Sigma) per g body 
weight by intraperitoneal injection and sacrificed 2h later. Pancreas was fixed in 4% (wt/vol) 
paraformaldehyde in PBS overnight at 4°C and embedded in paraffin wax. Tissue sections of 
2mm thickness were mounted on adhesive-coated slides and stained with H&E. 
For immunohistochemistry standard procedures were applied. Briefly, after deparaffinization 
and rehydration, heat-induced antigen retrieval with 0,01M citrate pH 6.0 was utilized. 
Endogenous peroxidase was blocked with 3% hydrogen peroxide for 15min at RT in the 
dark. Unspecific binding was blocked with 5% serum for 1h at RT. Slides were incubated with 
primary antibodies diluted in blocking solution over night at 4°C. Primary antibodies used 
include: anti-BrdU (1/250) (MCA2060 AbD Serotec), anti-F4/80 (1/100) (MF-48000 
Invitrogen), anti-CK19 (1/200) (TROMA III Developmental Studies Hybridoma Bank), anti-
Arginase 1 (1/500) (610708 BD Transduction Laboratories), anti-S100a4 (1/800) (13018 Cell 
Signaling Technology), anti-MMR/ CD206 (1/100) (AF2535 R&D systems Biotechne), anti-
Atg5 (1/100) (NB110-53818 Novus Biologicals), anti-p62 (1/100) (GP62-C Progen), and anti-
LC3 (1/100) (PD014 MBL International). Secondary antibodies including biotinylated anti-
rabbit in goat (BA 1000 Vector), anti-mouse in goat (BA 9200 Vector), and anti-rat in rabbit 
(BA 4000 Vector) were applied for 1h at RT and avidin-biotin peroxidase complex for 
biotinylated secondary antibodies was then added according to manufacturer directions 
(Vector Laboratories, CA). Staining was developed with DAB reagent (Vector Laboratories, 
CA). For Arginase 1 and S100a4 detection Streptavidin/Biotin blocking kit (SP2002 Vector) 
was used during the staining procedure to reduce background, according to manufacturer 
instructions. Hematoxylin was used for counterstaining. 
 
ADM and PanIN Quantifications 
Paraffin-embedded tissue sections from 4-week old Kras, A5+/-; Kras, A5; Kras were stained 
for H&E and photographed at 100x magnification. The number of Acinar to Ductal 
Metaplasias was determined in each picture using Zeiss axiovision software. Measurements 
from multiple photographs per tissue slide were summed up and expressed as ADM per High 
Power Field (HPF). Results were then averaged according to genotype. In a similar fashion, 
paraffin-embedded tissue sections from 9- and 18-week old Kras, A5+/-; Kras, A5; Kras were 
stained for H&E and photographed at 100x magnification. Pancreatic Intraepithelial 
Neoplasias (PanINs) were classified according to PanIN-1/-2/-3 and total numbers were 
expressed as PanIN/HPF. Results were then averaged according to genotype and age 
group. 
 
Co-immunofluorescence 
Cryo-sections of GFP-LC3 transgenic pancreas were processed as described above. 
Unspecific binding was blocked with 5% serum at RT and incubated over night at 4°C with 
the primary antibody. Anti-CK19 primary antibody (TROMA III Developmental Studies 
Hybridoma Bank) was diluted in blocking solution (1/200). At the following day secondary 
antibody anti-rat in goat Alexa Fluor 568 (1/300) (A11077 Invitrogen) was applied for 1h at 
RT. In the end, slides were covered with DAPI containing mounting medium (H-1200 Vector 
Laboratories) and analyzed with fluorescence microscopy (Zeiss Axiovert 200M).  
 
Transmission Electron Microscopy (TEM) 
For TEM Kras and A5+/-; Kras cells were collected and fixed in 2.5% electron microscopy 
grade glutaraldehyde in 0.1M sodium cacodylate buffer pH 7.4 (Science Services, Munich, 
Germany), postfixed in 2% aqueous osmium tetraoxide 4, dehydrated in gradual ethanol (30–
100%) and propylene oxide, embedded in Epon (Merck, Darmstadt, Germany) and cured for 
24 hours at 60°C. Pellets were cut in semithin sections and stained with toluidine blue. 
Ultrathin sections of 50nm were collected onto 200 mesh copper grids, stained with uranyl 
acetate and lead citrate before examination by transmission electron microscopy (Zeiss Libra 
120 Plus, Carl Zeiss NTS GmbH, Oberkochen, Germany). Pictures were acquired using a 
Slow Scan CCD-camera and iTEM software (Olympus Soft Imaging Solutions, Münster, 
Germany) 
 
RNA Extraction and Quantitative Real-Time Polymerase chain reaction (qRT-PCR) 
For RNA extraction, Kras and A5+/-; Kras cells were collected in RLT lysis buffer (1015762 
Qiagen) supplemented with 1% b-mercaptoethanol (M6250 Sigma) and snap frozen. 
Subsequently, RNA was extracted using the RNeasy Mini Kit (74104 Qiagen). SuperScript II 
Reverse Transcriptase (18064-014 Invitrogen) was used for complementary DNA (cDNA) 
synthesis. qRT-PCR was carried out using a StepOne Plus Real-Time PCR System (Applied 
Biosystems) in combination with Power SYBR Green PCR Master Mix (4368577 Applied 
Biosystems). Target mRNA expression was normalized to endogenous cyclophillin and 
quantified by the delta-delta CT method. Primer sequences are provided below.  
For detection of spliced Xbp1, cDNA was subjected to PCR with a primer set detecting both 
unspliced and spliced Xbp1 (unspliced Xbp1u 171 bp, spliced Xbp1s 145 bp). PCR products 
were separated by agarose gel electrophoresis. Cyclophilin was used as control. 
 
Gene Forward primer Reverse primer 
Sod1 GTCCGTCGGCTTCTCGTCT CACAACTGGTTCACCGCTTG 
Sod2 ACACATTAACGCGCAGATCA ATATGTCCCCCACCATTGAA 
Nrf1 TCTCACCCTCCAAACCCAAC CCCGACCTGTGGAATACTTG 
Nrf2 TTCTTTCAGCAGCATCCTCTCCAC ACAGCCTTCAATAGTCCCGTCCAG 
Xbp1 ACACGCTTGGGAATGGACAC CCATGGGAAGATGTTCTGGG 
Cyclophilin ATGGTCAACCCCACCGTGT TTCTGCTGTCTTTGGAACTTTGTC 
 
Microarray Data Analysis 
For transcriptomic analysis, Kras and A5+/-; Kras tumor cells were harvested after PBS-
washing in RLT lysis buffer supplemented with 1% b-mercaptoethanol, as described above. 
Cell suspensions were snap frozen and stored at -80°C. RNA isolation from tumor cell 
suspensions and Affymetrix GeneChip (Mus musculus) Mouse Gene 1.0 ST Array was 
conducted by the service facility KFB Center of Excellence for Fluorescent Bioanalytics 
(Regensburg, Germany, www.kfb-regensburg.de). Microarray data were analyzed by using 
the Gene Set Enrichment Analysis Software (GSEA) provided by the Broad Institute. A 
Nominal Enrichment Score (NES) of ≥1.0 and a nominal p-value of <0.05 were used to 
evaluate significantly upregulated pathways according to KEGG and Transcription Factor 
Binding Motif databases. Pathways were subsequently separated into groups depending on 
their description in the respective database. A heat map of the most highly regulated genes 
computed by GSEA was used and the genes were further classified according to their 
function. Genes belonging to one functional group were depicted as percentage related to 
the entire number of highly regulated genes. A NES versus nominal p value diagram was 
provided to indicate the total number of regulated (NES≥0.5) and significantly regulated 
(NES≥1.4, nominal p value< 0.05) pathways detected in the KEGG database. Microarray 
data are available in the ArrayExpress database at EMBL-EBI 
(https://www.ebi.ac.uk/arrayexpress/) under accession number E-MTAB-6275. 
 
Non-targeted metabolomic measurements 
LC-MS/MS–based non-targeted metabolomics analysis was conducted at the Genome 
Analysis Centre, Helmholtz Zentrum München as previously described 5. About 1x106 
pancreatic cancer cells were required for the analysis. In brief, 0.375x106 Kras or A5+/-; Kras 
cells were seeded in duplicates in a 6-well plate with 2 ml culture medium and grown for 48h 
until 80-90% confluent and an approximate number of 0.5x106 was reached. Cells were 
washed two times with PBS (37°C). Dry ice cold 80% v/v methanol (400 ml) containing 4 
recovery standard compounds to monitor extraction efficiency was added to the cells to 
cover them immediately. Cells were scraped and the cell suspension was transferred into 
precooled (dry ice) 2 ml screw cap micro tubes (Sarstedt Micro tube 2 ml, PP (Reference #: 
72.694.005)) filled with 160 mg glass beads. Another 100 ml of dry ice cold methanol 
extraction solvent to wash the well was added and transferred to the micro tube. 
Suspensions of two 6-wells were pooled into one tube to obtain a sample of 1x106 cells in 1 
ml cell suspension. The samples were stored immediately at -80°C until metabolomic 
analysis was performed. The metabolites were assigned to cellular pathways based on 
PubChem, KEGG, and the Human Metabolome Database. Metabolic pathways were 
described as significantly up- or down-regulated, when metabolites assigned to those 
specific pathways were increased or decreased, respectively. Values depicted correspond to 
the absolute values normalized in terms of raw area counts after LC/MS-based metabolomic 
analysis. 
 
Oncomine database 
The oncomine database (www.oncomine.org) was used to search for autophagy and 
lysosomal function-associated genes. GO Biological Process-Autophagy or GO Cellular 
Component-Lysosome was used as concept; primary filters selected were Cancer versus 
Normal Analysis and Pancreatic Cancer; pathology subtypes M1+, N1+, T4 according to 
TNM-staging were subsequently applied. DNA Copy Number (log2 copy number units) 
retrieved from the Cancer Genome Atlas (TCGA Research Network, 
http://cancergenome.nih.gov/) was used to illustrate copy number gain or loss in human 
pancreatic cancer samples versus normal pancreas samples.  
 
Measurement of mitochondrial metabolism by seahorse analyzer 
Measurements of oxygen consumption rate (OCR) were performed with a XF extracellular 
flux analyzer as described previously (Oelkrug R, Goetze N, Exner C, Lee Y, Ganjam GK, 
Kutschke M, Muller S, Stohr S, Tschop MH, Crichton PG, Heldmaier G, Jastroch M, Meyer 
CW. Brown fat in a protoendothermic mammal fuels eutherian evolution. Nature 
communications 2013;4:2140). Briefly, Kras and A5+/-;Kras tumor cells were seeded at a 
density of 1X105 cells per well in a XF24 cell culture microplate. DMEM (4.5 g/L glucose, +L-
Glutamine, -Pyruvate, pH 7.6 at RT) supplemented with 10% heat inactivated FBS (Gibco) 
and 1% Pen/Strep was used for cell culturing. On the day of assay (24h after seeding), 
medium was exchanged to non-carbonated Seahorse measurement medium and the XF24 
plate was transferred to a temperature-controlled (37 °C) XF24 Extracellular Flux analyzer 
(Seahorse Bioscience) and equilibrated for 10 min. To determine the basal respiration four 
assay cycles (1-min mix, 2-min wait and 3-min measuring period) were used. Then 
oligomycin (4 ?M) was added by automatic pneumatic injection (three assay cycles) to 
inhibit ATP synthase and thus approximate the proportion of respiration used to drive ATP 
synthesis versus proton leak-linked respiration. Oligomycin was followed by an injection of 
FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone) (0.5  ? M) to completely 
dissipate proton motive force and maximally stimulate mitochondrial respiration (three assay 
cycles), thus determining spare respiratory capacity and substrate oxidation capacity. An 
injection of rotenone (4 ?M) and antimycin A (2 ?M) was used to correct for the non-
mitochondrial respiration rate (three assay cycles), which was subtracted from all the other 
rates. Coupling efficiency was calculated as the oligomycin-sensitive fraction of mitochondrial 
respiratory activity, estimating the proportion of basal respiration used to drive ATP 
synthesis. To determine extracellular acidification rates (ECARs) for glycolysis, experiments 
were ended by injection of 2-DG (2-deoxy-D-glucose, 100 mM), correcting for non-glycolytic 
acidification. Injection of 2-DG enabled calculation of glycolytic acidification. Data obtained 
after oligomycin treatment induce glycolytic capacity. OCR was plotted against ECAR to 
illustrate oxidative versus glycolytic metabolism in cancer cells. Raw data were normalized to 
either protein or DNA content (ng).  
 
Cell morphology analysis and quantification of cell proliferation 
To analyze cell morphology, Kras and A5+/-; Kras were seeded in 6-well plates. 24h after 
seeding, pictures were acquired with the Zeiss Axiovision Imager A1 using a magnification of 
100x. For quantification of proliferation, 5x104 Kras and A5+/-; Kras cells were seeded per 
well in a 6-well plate. The culture media was changed every other day. Cells were counted 
after trypsinization every 24 hours up to 120 hours using the neubauer counting chamber. 
Full medium Dulbecco’s modified Eagle medium (DMEM) supplemented with 10%FBS 
(#10082147; Gibco), 1% PenStrep (#1500-063; Gibco), 1%NEAA (#11140050; Gibco) was 
used for cell culture. 
 
Autophagic flux measurement using Cyto-ID 
To analyze autophagosome accumulation, Kras and A5+/-; Kras were seeded in triplicates in 
96-well plates and allowed to adhere overnight. Half of the cells were kept in full medium and 
compared to cells cultivated overnight in serum-free medium. Autophagosome accumulation 
was analyzed by using the CYTO-ID Autophagy Detection Kit (Enzo, ENZ-51031) according 
to the manufacturer’s instructions. Fluorescence was detected using a Varioscan Lux 
(Thermo scientific) microplate reader. 
 
Colony formation and cell treatments 
For the cologenic assay, 3x102 Kras and A5+/-; Kras cells were plated in triplicates six-well 
plates and grown for 10d in culture media. Colonies were stained with 2% crystal violet 
(C3886; Sigma), washed with water, and their area was quantified using ImageJ. Treatments 
during the clonogenic assays include: 10% FCS-containing medium, serum-free HBSS-
containing medium (Hanks´Balanced Salt Solution GIBCO-14025092, 1:20 dilution of normal 
medium), chloroquine in full medium (2µM and 6 µM, C6628 SIGMA), 6-Aminonicotinamide 
in full medium (10µM and SIGMA-A68203), Rotenone in full medium (15nM and SIGMA-
R8875), Galactose and Glutamine in glucose free medium (Galactose 10mM and Glutamine 
4mM, D-(+)-Galactose, SIGMA-G5388 and GlutaMAX-I, GIBCO-35050061, DMEM, no 
glucose, GIBCO-11966-025), High Glucose in glucose free medium (25mM and GIBCO-
A2494001). 
 
Anoikis assay 
For the anoikis assay, 6-well plates were coated with poly-HEMA (20mg/ml) (P3932; Sigma) 
dissolved in 96% ethanol. 5x105 Kras and A5+/-; Kras cells were seeded in triplicates and 
cultured for 48h in culture media. Surviving cells in the media were calculated using the 
neubauer counting chamber. 
 
Boyden Chamber Migration Assay 
1.5x105 Kras and A5+/-; Kras cells were seeded in triplicates in 6-well plates till confluence. 
100 µL serum free medium was added to upper chamber and 200 µL cells were added to 
chamber (2.5x105/mL in serum free medium). 750 µL full medium was added to lower 
chamber. Boyden-Chamber Assay plate was incubated at 37oC for 12-16 hours. After 
incubation, medium was removed from upper chamber and chambers were washed twice 
with PBS. Cells were fixed with formaldehyde (3.7% in PBS) for 2 minutes and washed with 
PBS twice. To permeabilize cells, 100% methanol was added to chambers for 20 minutes. 
After removing methanol chambers were washed twice with PBS. Chambers were place into 
wells and stained with Giemsa at room temperature for 15 minutes. After removing Giemsa 
solution, chambers were washed twice with PBS. Non-migrated cells were scraped off with 
cotton swabs from the membranes. Migrated cells were counted under a light microscope.  
 
Invasion assay 
6.5mm Transwell (#CLS3464; Sigma, Corning Costar, USA) with 8.0 µm Pore polyester 
membrane insert was used in 24-well culture plates. The upper surface of the membrane 
was coated with 100ml mixed matrigel (corning Life Sciences) per well. The matrigel was 
incubated at 37°C for gelling. 5x104 Kras and A5+/-; Kras cells were seeded in triplicates with 
200µl serum-free DMEM in the upper chamber. The lower chamber was filled with 750 µl of 
culture media. After 48h, the cells were fixed by formaldehyde 3.7% in PBS, permeabilized 
with 100% methanol and stained with crystal violet. Cells that invaded to the lower surface 
area of the membrane were calculated by counting stained cells. E64d (100 µM and E3132-
SIGMA) was used to inhibit cathepsin activity. Filopodia were quantified after 36h of seeding. 
 
Orthotopic Transplantation 
Littermates of A5+/-; Kras mice 8 weeks of age were injected orthotopically into the pancreas 
with 1×106 of either Kras or A5+/-; Kras tumor cell suspensions (resuspended in a solution of 
Matrigel (Corning 354234)/ DMEM without supplements in a ratio of 4/1) using a 26G needle. 
The mice were sacrificed 30 d after injection, or earlier when they reached sickness criteria. 
Pancreatic tissues were collected, embedded in paraffin and stained with haematoxylin and 
eosin (H&E). Lung, liver, lymph nodes, kidney, spleen, and duodenum were also collected 
and processed in the same way. Occurrence of tumors and metastasis was quantified and 
representative macroscopic and microscopic pictures were taken. 
 
Tail vein injection 
Littermates of A5+/-; Kras mice 8 weeks of age were injected intravenously through the tail 
vein with 1×106 of either Kras or A5+/-; Kras tumor cell suspensions (resuspended in 0,9% 
saline solution) using a 26G needle. The mice were sacrificed 20 d after injection, or earlier 
when they reached sickness criteria. The lungs were collected, embedded in paraffin and 
stained with haematoxylin and eosin (H&E). Mice were classified as metastasis positive or 
negative and representative macroscopic and microscopic pictures were taken. Body weight 
at time of sacrifice was measured to establish levels of cachexia. Metastatic tumor cells were 
re-isolated from pieces of lung tissue to determine cell morphology and survival capacity. 
 
Liposomal clodronate treatment 
For macrophage depletion in wildtype mice, clodronate-loaded liposomes (CP-010-010, 
Liposoma) were used. As control, mice were injected with control liposomes (PBS). For the 
experiment, mice were injected intraperitoneally (ml/ mouse) as follows:  
 
Prior to tail vein injection After tail vein injection 
Day -8 Day -4 Day 0 Day 4/ 8 Day 12/16 Day 20 
0.2 ml 0.2 ml 0.1 ml 0.1 ml 0.1 ml 0.1 ml 
 
Clodronate and PBS treated mice were injected with A5+/-;Kras cells (biological duplicates) 
into the tail vein (at Day 0 according to the scheme above) to analyze the influence of 
macrophages on metastasis in the lung. Experiments were performed with at least 5 mice 
per group. Mice were sacrificed 21 days after tail vein injection due to sickness. Spleens of 
mice were analyzed after the experiments for F4/80 immunohistochemistry as described 
above. Lung metastasis was quantified as described below. 
 
Cytokine array 
In order to detect cellular cytokine profile supernatants of Kras and A5+/-; Kras cells were 
collected and processed as described above for immunoblotting. Lysates were then used 
according to the manufacturer’s instructions (Mouse Cytokine Array Panel A, Catalog 
Number ARY006, R&D Systems). Pixel intensity of individual plots was quantified using 
ImageJ software. The average of two spots corresponding to one cytokine was used to 
compare cytokine profile according to genotype. 
 
Macrophage differentiation assay 
To detect the effect of Kras and A5+/-; Kras cells on macrophage phenotype, Kras and A5+/-
;Kras cells were seeded in 6-well plates and cultivated for 48h. Supernatants were collected 
and applied on Raw macrophages (RAW 264.7 (ATCC® TIB-71™) cultivated in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10%FBS (#10082147; Gibco), 1% 
PenStrep (#1500-063; Gibco), 1%NEAA  (#11140050; Gibco). Macrophage phenotype was 
monitored and assessed by microscopy as described 6. 
For Arginase-1 Immunofluorescence macrophages were treated as described above and 
subsequently stained with anti-Arginase 1 (1/500) (610708 BD Transduction Laboratories). 
Briefly, unspecific binding was blocked with 5% serum at RT and cells were incubated over 
night at 4°C with the primary antibody. At the following day secondary antibody anti-mouse in 
goat Alexa Fluor 488 (1/300) (A-11001 Invitrogen) was applied for 1h at RT. In the end, 
slides were covered with DAPI containing mounting medium (H-1200 Vector Laboratories) 
and analyzed with fluorescence microscopy (Zeiss Axiovert 200M).  
 
Measurement of Ca2+ responses 
To measure Ca2+ responses, Kras and A5+/-;Kras cells were loaded with Fluo-4 by 
incubation with Fluo-4/AM (5μM) for 60min at room temperature (approximately 23oC) in Na-
Hepes-based solution (140mM NaCl, 4.7mM KCl, 1.13mM MgCl2, 10mM HEPES, 10mM 
Glucose, 1.8mM CaCl2, pH7.4). After that cells were washed by perfusion (gravity-based 
perfusion system) with the Na-Hepes-based solution and imaged every 2sec over a time 
period of 800sec using a Zeiss 510 confocal made  (excitation 488nm, emission LP505). 
Heat Inactivated FBS (0.01% or 0.05% diluted in the Na-Hepes-based solution) was applied 
when 200sec of recording were reached. 
Fluorescent responses (F) were normalized to fluorescence F0 recorded before the addition 
of FBS (average fluorescence value for measurements recorded during 190 - 200sec time 
interval). Amplitude of cytosolic Ca2+ responses was determined by the equation ((Fmax-
F0)/F0=DFmax/F0, with Fmax corresponding to the maximum Fluo-4 fluorescence measured 
during the 200-500sec interval. Amplitude of cytosolic Ca2+ responses of each single cell 
over 5min of FBS application was measured and the amplitudes were then averaged for 
each genotype (n > 170 cells for each genotype).  
Cells responding to FBS were defined as cells exciding 20% elevation threshold of 
normalized fluorescence (F/F0) in the first 5min of FBS application. 
 
Quantification of primary tumor and metastasis burden (iv and orthotopic TP; also 
with liposomal clodronate treatments) 
For quantification of primary tumor and metastasis burden (in all orthotopic transplantation 
and tail vein injection experiments) 2 mm-tissue slices were stained with H&E. Per H&E slide 
multiple pictures at 100x magnification were taken. Area (mm2) of tumor foci in pancreas and/ 
or lung tissues was calculated and expressed as % to all tissue area using a proprietary 
software package (Zeiss Axiovision, Oberkochen, Germany). Statistical analysis was done in 
between the genotypes (mean ± standard deviation (SD), Student t test). 
 
Quantification of F4/80-positive and CD206-positive macrophages 
For quantification of F4/80-positive macrophages in the lungs of tail vein-injected mice, tissue 
sections were stained for F4/80 via immunohistochemistry, as described above. Sections 
were subsequently photographed at 200x magnification. Number of positive cells was 
determined with Zeiss axiovision software. Sum from multiple photographs per tissue slide 
were generated and expressed in relation to the number of high power fields counted. 
Results were then averaged by genotype. 
F4/80-positive and CD206-positive macrophages were also quantified in the original tumors 
of Kras and A5+/-;Kras mice. For this, tissue slides were stained with the respective 
antibodies and the % of positive nuclei/ all nuclei were determined. 
 
Human sample analysis 
For ATG5 immunoblotting, a total of 67 human PDAC samples (Supplementary Table 2, 
Cohort 1) collected from the MTBIO tissue bank of the Institute of Pathology at the Technical 
University Munich, were analyzed as described above. Band density was quantified by using 
ImageJ and normalized to β-Actin. From these 67 patients, n=56 with known survival were 
grouped into ATG5 low-moderate expression (ATG5/ β-Actin ratio below 0,5) and high 
expression (ATG5/ β-Actin ratio equal/ above 0,5) and used for Kaplan-Meier survival 
analysis with GraphPad Prism.  
For ATG5 immunohistochemistry, two different cohorts (Cohort 2 and Cohort 3) were used. 
Cohort 2 consisted of 26 primary PDACs and their corresponding distant metastases that 
were resected between 2008 and 2013 at the University Hospital Heidelberg (Supplementary 
Table 3). The use of this tumor cohort for biomarker analysis has been approved by the 
ethics commission of the Klinikum rechts der Isar, Technische Universität München 
(403/17S). Primary tumor samples were used for ATG5 immunohistochemistry as described 
below for Cohort 3 and 19 of these were evaluated as described below for Cohort 3. In this 
analysis 4 patients from the Cohort 3 also exhibiting distant metastasis were included as 
well. The percentages of patients with distant metastasis in the low-moderate and in the high 
ATG5-expressing groups were calculated as described below for Cohort 3. 
Cohort 3 consisted of a patient cohort with primary resected PDACs. The cohort was 
investigated previously in several studies 7-9 and included 200 individuals (Supplementary 
Table 4) that received partial pancreatoduodenectomy for PDAC between 1991 and 2006 at 
the Charité University Hospital Berlin. The use of this tumor cohort for biomarker analysis 
has been approved by the Charité University ethics committee (EA1/06/2004). 
Tissue microarrays of both IHC cohorts were generated as previously described 7, 10. In detail 
three tumor cores (diameter 1.5 mm) of representative tumor areas selected by a board 
certified pathologist on H&E stained slides were punched out of formalin-fixed paraffin 
embedded (FFPE) tissue blocks and arranged in a newly generated paraffin block. TMAs 
were made using a tissue microarrayer (Beecher Instruments, Sun Praierie, USA). Staging of 
both cohorts followed the WHO recommendations at the time of cohort generation (TNM-
classification of the 7th edition). Clinical and demographic information was obtained from the 
respective institutional patient databases, by reviewing medical charts and pathological 
reports. Patient follow-up data were obtained from clinical records and via direct contact with 
patients and/ or their relatives. For Immunohistochemistry, 2µm sections prepared with a 
rotary microtome (HM355S, ThermoFisher Scientific, Waltham, USA) were collected from 
134 patients in this cohort (Supplementary Table 3). Immunohistochemistry was performed 
using a Bond RXm system (Leica, Wetzlar, Germany, all reagents from Leica) with a primary 
antibody against ATG5 (NB110-53818 Novus Biologicals). Briefly, slides were deparaffinized 
using deparaffinization solution, pretreated with Epitope retrieval solution 1 (corresponding to 
citrate buffer pH 6) for 20 minutes. Antibody binding was detected with a polymer refine 
detection kit without post primary reagent and visualized with DAB as a dark brown 
precipitate. Counterstaining was done with hematoxyline. The membranous ATG5 was 
scored according to the percentage and intensity of positive cells on a 0 to 3+ scale 
(negative as score 0, faint expression as score 1+, moderate expression as score 2+ and 
strong expression as score 3+; see Figure 7B for a panel of staining). Kaplan-Meier survival 
analysis was performed by GraphPad Prism with a total of 79 patients from the 134. Patients 
with no available survival and patients with no death follow up were removed from the 
analysis. The two groups in the Kaplan-Meier analysis included low-moderate ATG5-
expressing patients (with scores 1 and 2) and high ATG5-expressing patients (score 3). 
Lymph node status and resection status in these patients was expressed as % patients 
referring to the total patients belonging to the two groups. 
 
An overview of the three different cohorts used can be found in the following table: 
 
Cohort 
number 
Status Site Analysis Number of 
patients 
1 Postoperative Primary Western blot 56 
2 Palliative/ 
metastatic 
Primary IHC 23 
3 Postoperative Primary IHC 79 
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Supplementary Figure 1: Relating to Figure 1. 
(A) GFP-LC3 and CK19 immunofluorescence of A5;Kras mice expressing transgenic GFP-
LC3; white arrowhead indicates diffuse GFP-LC3 staining; nuclei are detected with DAPI. (B) 
Macroscopic and microscopic appearance of pancreata from 18-week old Atg5 deficient 
(A5;Kras) and Atg5 heterozygous mice (A5+/-;Kras) compared to 18-week old Atg5 proficient 
mice (Kras); oncogenic Kras is expressed in all groups of mice. (C) Pancreas/Body weight 
ratio in 4-/9-/18/ and more than 18-week old Kras, A5+/-;Kras, and A5;Kras mice (n≥3). (D) 
Quantification of Acinar-to-Ductal Metaplasia (ADM) per High Power Field (HPF) in 4-week 
old Kras, A5+/-;Kras, A5;Kras mice (n≥4). (E) Quantification of PanIN-1/-2/-3 per High Power 
Field (HPF) in 9-/ 18-week old Kras, A5+/-;Kras, and A5;Kras mice (n≥3). (F) Kaplan-Meier 
survival curve of Kras (n=54), A5+/-;Kras (n=13), and A5;Kras (n=24) mice (Median survival 
475, 451, 184 days respectively; ***P<0.0001 comparing Kras and A5;Kras). Mean±SD, 
*P<0.05, **P<0.01, ***P<0.001. Scale bars equal 50μm. 
 
  
Supplementary Figure 2: Relating to Figure 2. 
Colony formation assays in Kras and A5+/-;Kras cells after (A) 10% FCS cultivation, (B) 6-AA 
(6-Aminonicotinamide), (C) Rotenone, (D) Galactose/ Glutamine, and (E) high glucose 
treatment. Graphs are shown on the left, representative pictures on the right. Mean±SD 
(n=3). 
 
  
Supplementary Figure 3: Relating to Figure 3. 
(A) Representative macroscopic and microscopic pictures of pancreatic tumors from wildtype 
mice after orthotopic transplantation (TP) of Kras and A5+/-;Kras cells; primary tumors are 
shown on the top, tumors formed after transplantation in the fourth picture from the top, and 
CK19 immunohistochemistry on the bottom; Quantification of primary pancreatic tumor 
burden in mice after orthotopic transplantation of Kras and A5;Kras cell lines (% area of 
tumor tissue, n>3) (bottom). (B) Representative macroscopic and microscopic pictures of 
metastasis (lung, LN=lymph node, spleen) after TP of A5+/-;Kras cells into wildtype mice; 
white arrowheads indicate metastasis (top); metastasis incidence (%) after TP of Kras and 
A5+/-;Kras cells (n≥5) (bottom). (C) Representative macroscopic picture of wildtype mice 
after tail vein (i.v.) injection of Kras and A5+/-;Kras cells (left), and quantification of body 
weight in male and females (n≥3) (right). (D) H&E picture of liver and spleen metastasis after 
i.v. of A5+/-;Kras cells; asterisks indicate metastasis (top); representative bright field pictures 
of Kras and A5+/-;Kras cells isolated from the lung of wildtype mice after i.v.; asterisk and 
circle indicate two different cell populations (bottom). (E) Colony formation assay in Kras, 
A5+/-;Kras, and Kras cells after 58, 94% knockdown (KD) of Atg5 (n>3) (left); representative 
pictures are shown (right); cells were cultivated in medium with 10% FCS. Mean±SD, 
*P<0.05. Scale bars equal 50μm. 
  
Supplementary Figure 4: Relating to Figure 4. 
(A) Classification of significantly enriched gene sets into categories, based on Transcription 
Factor Binding Motif database for Kras (left) and A5+/-;Kras (right) cells; pie charts show 
classification and tables highlight examples of enriched pathways (NES≥1.0, P<0.05; P value 
0.0 indicates P<0.001). (B) GSEA diagrams of significantly enriched KEGG pathways found 
in Kras (top) and A5+/-;Kras (bottom) cells. (C) Heat map of most highly regulated genes 
identified by GSEA in Kras and A5+/-;Kras cells. 
 
  
Supplementary Figure 5: Relating to Figure 5. 
(A) Analysis of phospho-AMPKa, AMPKa, phospho-S6, mitochondrial complexes (COX I, 
COX II/IV, ATP Core 2), SOD2, and BiP in protein lysates and Xbp1 splicing 
(Xbp1u=unspliced, Xbp1s=spliced) in RNA-preparations from Kras and A5+/-;Kras cells; β-
Actin and cyclophilin were used as loading controls. (B) Coupling efficiency (%) of 
mitochondria in Kras and A5+/-;Kras cells as measured by seahorse (n≥30). (C) qRT-PCR of 
Sod1 and Nrf2 in mRNA extracts from Kras and A5+/-;Kras cells; data are normalized to 
cyclophilin (n=3). Mean±SD. 
 
  
Supplementary Figure 6: Relating to Figure 6. 
(A) Proportions of Kras and A5+/-;Kras cells producing Ca2+ responses after stimulation with 
0.01% or 0.05% FBS (n>170). (B) Cathepsin B (CTSB) extracellular activity (% extracellular 
activity versus total activity) as measured from supernatants of Kras and A5+/-;Kras cells 
(n=15). (C) Western blot analysis of Pro-cathepsin B (Pro-CTSB), Pro-cathepsin D (CTSD), 
and Pro-cathepsin L (Pro-CTSL) in supernatants of Kras and A5+/-;Kras cells. (D) Colony 
formation assay in Kras and A5+/-;Kras cells after cultivation with E64d. (E) Illustration of 
lysosome-associated DNA copy number gain (red) or loss (blue) (TCGA data) in normal 
pancreas versus pancreatic ductal adenocarcinoma (PDAC) samples (log2 copy number 
units). Mean±SD. 
 
  
Supplementary Figure 7: Monoallelic loss of Atg5 induces pro-tumorigenic 
inflammation. 
(A) Cytokine profile expression shown by immunoblotting of protein lysates from Kras and 
A5+/-;Kras supernatants (left); quantification of average pixel intensity between two dots 
corresponding to the same cytokine; numbers above graph correspond to dot-position in plot 
(n=1). (B) Quantification of M1 and M2 macrophages (% of all macrophages) according to 
their morphology after stimulation with supernatants from Kras and A5+/-;Kras cells (n≥3); 
representative bright field pictures are shown indicating morphology of undifferentiated 
(asterisk), M1 (white arrowhead), and M2 (black arrowhead) macrophages (left); Arginase-1 
immunofluorescence in macrophages after stimulation with supernatants from Kras and 
A5+/-;Kras cells; nuclei are detected with DAPI (right). (C) Representative 
immunohistochemistry pictures of F4/80 and CD206 in primary tumors from Kras and A5+/-
;Kras mice (top); quantification of F4/80 and CD206-positive macrophages (% positive 
nuclei) in Kras and A5+/-;Kras primary tumors (n>3). (D) Immunohistochemical quantification 
of F4/80-positive cells per high power field (HPF) in the lungs of mice after i.v. with Kras and 
A5+/-;Kras cells (n=20) (left); representative F4/80 and Arginase 1 (Arg1) 
immunohistochemistry in tissue sections from the lungs of mice after tail vein injection (i.v.) 
with Kras and A5+/-;Kras cells; black arrowheads indicate F4/80-positive macrophages 
(right). (E) Quantification of lung metastasis (% area) after tail vein injection of A5+/-;Kras 
cells into PBS or clodronate-treated wildtype mice (n>3) (left); representative H&E pictures of 
the lung and F4/80 immunohistochemistry pictures of the spleen after the respective 
treatments. Mean±SD, *P<0.05, **P<0.01, ***P<0.001. Scale bars equal 50μm. 
 
  
Supplementary Table 1: PDAC and Metastasis in A5+/-;Kras mice 
List of A5+/-;Kras mice that were used for Pancreatic Adenocarcinoma (PDAC) and 
metastasis quantification; mouse number (ID), Gender, Age (days), PDAC incidence, 
Histology, liver/ lung/ diaphragm metastasis, ascites incidence, and other abnormalities are 
presented; Male=M, Female=F, Yes=Y, No=N, Ductal=D, Undifferentiated=U, lymph node 
infiltration=LN, Spleen infiltration=Spl, Kidney infiltration=Kd 
 
  
ID Gender Age PDAC Histology Liver Lung Diaphragm Ascites Others 
7135 F 698 Y D N N N N  
9138 F 293 Y D Y N N N LN 
9137 F 340 Y D Y Y Y Y LN 
9384 F 453 Y D Y Y Y Y Spl 
2835 M 389 Y U N N N N  
M5683 M 133 N N N N N N  
M5681 M 346 Y D Y Y Y Y LN 
M5617 F 385 Y D N Y N N  
M5618 M 451 Y D N Y Y N  
M5551 M 578 Y D Y Y N Y LN 
P642 M 673 Y D Y N Y Y LN/Spl/Kd 
M6215 F 451 N N N N N N  
Supplementary Table 2: Human pancreatic cancer patient cohort (postoperative, 
Cohort 1). 
List of the analyzed human pancreatic cancer samples for ATG5-western blot (n=67), 
collected from the MTBIO tissue bank of the Institute of Pathology at the Technical University 
Munich. Histology (Pancreatic Ductal Adenocarcinoma (PDAC)), extent of primary tumor (T), 
lymph node infiltration (N), metastasis (M), tumor differentiation grade (G), survival (months), 
ATG5 protein expression normalized to b-Actin and quantified by ImageJ (ATG5), and Tumor 
stage are shown. Samples marked with red or containing an X were not used in the analysis. 
The last 4 samples did not have patient data and were excluded from the study. 
 
Histology T N M G Survival ATG5 Stage 
PDAC 4 1 1 3 13 1.035 IV 
PDAC 3 1 1 3 12 0.304 IV 
PDAC 3 1 1 3 9 0.460 IV 
PDAC 3 1 1 3 11 0.030 IV 
PDAC 3 1 1 2 7 0.000 IV 
PDAC 4 1 0 3 9 0.472 III 
PDAC 4 1 0 3 12 0.144 III 
PDAC 4 1 x 2 17 0.369 III 
PDAC 4 1 x 2 5 0.294 III 
PDAC 3 1 0 4 13 0.529 III 
PDAC 3 1 0 3 26 0.624 IIB 
PDAC 3 1 x 3 10 0.554 IIB 
PDAC 3 1 x 3 29 0.685 IIB 
PDAC 3 1 x 3 29 0.698 IIB 
PDAC 3 1 0 3 7 0.873 IIB 
PDAC 3 1 0 3 4 0.769 IIB 
PDAC 3 1 0 3 5 0.016 IIB 
PDAC 3 1 0 3 3 0.488 IIB 
PDAC 3 1 0 3 lost to FU 0.621 IIB 
PDAC 3 1 0 3 10 0.491 IIB 
PDAC 3 1 0 3 4 0.526 IIB 
PDAC 3 1 0 3 14 1.308 IIB 
PDAC 3 1 0 3 9 0.966 IIB 
PDAC 3 1 0 3 17 1.005 IIB 
PDAC 3 1 0 3 11 0.428 IIB 
PDAC 3 1 0 3 lost to FU 0.838 IIB 
PDAC 3 1 0 3 lost to FU 0.042 IIB 
PDAC 3 1 0 2 3 0.380 IIB 
PDAC 3 1 0 2 29 0.382 IIB 
PDAC 3 1 0 2 25 0.350 IIB 
PDAC 3 1 0 2 34 0.649 IIB 
PDAC 3 1 0 2 46 0.548 IIB 
PDAC 3 1 0 2 31 0.758 IIB 
PDAC 3 1 0 2 lost to FU 0.167 IIB 
PDAC 3 1 0 2 10 0.115 IIB 
PDAC 3 1 0 2 40 0.157 IIB 
PDAC 3 1 0 2 3 0.964 IIB 
PDAC 3 1 x 2 13 0.258 IIB 
PDAC 3 1 x 2 10 0.255 IIB 
PDAC 3 1 0 1 24 0.777 IIB 
PDAC 3 1 0 1 56 0.210 IIB 
PDAC 3 1 X 
 
14 0.535 IIB 
PDAC 2 1 0 1 23 0.101 IIB 
PDAC 1 1 0 3 60 0.047 IIB 
PDAC 3 0 0 3 4 0.805 IIA 
PDAC 3 0 0 3 31 0.461 IIA 
PDAC 3 0 x 3 18 0.486 IIA 
PDAC 3 0 x 3 8 0.539 IIA 
PDAC 3 0 0 3 76 2.504 IIA 
PDAC 3 0 0 3 10 0.653 IIA 
PDAC 3 0 0 3 lost to FU 0.502 IIA 
PDAC 3 0 0 2 32 0.911 IIA 
PDAC 3 0 x 2 21 0.303 IIA 
PDAC 3 0 0 2 10 0.052 IIA 
PDAC 3 0 x 2 39 0.388 IIA 
PDAC 3 0 0 2 36 0.298 IIA 
PDAC 3 0 0 2 30 1.674 IIA 
PDAC 3 0 0 2 18 0.572 IIA 
PDAC 3 0 0 2 lost to FU 0.405 IIA 
PDAC 3 0 x 1 23 0.747 IIA 
PDAC 3 0 x 1 34 0.181 IIA 
PDAC 2 0 0 3 lost to FU 0.533 IB 
PDAC 2 0 0 2 23 0.098 IB 
PDAC 
     
0.848 
 PDAC 
     
0.006 
 PDAC 
     
0.312 
 PDAC 
     
0.493 
  
 
Supplementary Table 3: Human pancreatic cancer patient cohort (palliative/ 
metastatic, Cohort 2). 
List of the analyzed human pancreatic cancer samples for ATG5-immunohistochemistry 
(n=26). Each row represents one individual diagnosed with PDAC (Pancreatic Ductal 
Adenocarcinoma, as mentioned beneath the headline Histology) and exhibiting distant 
metastasis (M1, i.e., HEP=hepatic, PER=peritoneal, SKI=skin, ADR=adrenal). Patients were 
resected between 2008 and 2013 at the University Hospital Heidelberg. ATG5 protein was 
detected by immunohistochemistry; membranous ATG5 was scored according to the 
percentage and intensity of positive cells on a 0 to 3+ scale (negative as score 0, faint 
expression as score 1+, moderate expression as score 2+ and strong expression as score 
3+). The sum score is provided in the second column. Patients without ATG5 score were 
excluded from the analysis. 
 
Histology ATG5 M1  
PDAC 2.3 HEP, PER 
PDAC 3 HEP 
PDAC 
 
HEP 
PDAC 2.8 HEP 
PDAC 1 HEP 
PDAC 
 
HEP, PER, ADR 
PDAC 
 
HEP 
PDAC 2.9 HEP 
PDAC 
 
HEP 
PDAC 2 PER 
PDAC 2 PER 
PDAC 2.8 PER 
PDAC 3 HEP 
PDAC 2.1 HEP 
PDAC 1.8 HEP 
PDAC 2.5 HEP 
PDAC 2 SKI 
PDAC 2.9 HEP 
PDAC 1.9 HEP 
PDAC 
 
HEP 
PDAC 
 
HEP 
PDAC 3 HEP 
PDAC 2.1 HEP 
PDAC 
 
SKI 
PDAC 3 HEP 
PDAC 3 HEP 
 
 
Supplementary Table 4: Human pancreatic cancer patient cohort (postoperative, 
Cohort 3). 
List of the analyzed human pancreatic cancer samples for ATG5-immunohistochemistry 
(n=134). Each row represents one individual diagnosed with PDAC (Pancreatic Ductal 
Adenocarcinoma) at the Charité University Hospital Berlin. Event of death (yes=1, no=0), 
Survival (days), lymph node status (pN), metastasis status (pM), tumor stage (pT), patient 
characteristics (gender, age), UICC tumor staging, and resection margin (R) are shown. 
ATG5 protein was detected by immunohistochemistry; membranous ATG5 was scored 
according to the percentage and intensity of positive cells on a 0 to 3+ scale (negative as 
score 0, faint expression as score 1+, moderate expression as score 2+ and strong 
expression as score 3+). The sum score is provided in the first column. Patients without 
death event and no registered survival were removed from the analysis. 
 
ATG5 Death Survival pN pM pT Gender Age Stage R 
2.7 1 431 0 0 2 w 74 Stage I 0 
2 1 898 1 0 2 w 75 Stage IIB 0 
1 0 
 
0 0 3 w 64 Stage IIA 0 
2.7 0 5748 1 0 3 w 56 Stage IIB 1 
3 1 278 1 0 3 m 47 Stage IIB 0 
1 1 780 1 0 2 m 67 Stage IIB 0 
3 1 407 1 0 3 w 62 Stage IIB 0 
2.4 1 452 1 1 3 m 31 Stage IV 1 
3 1 1166 1 0 2 w 63 Stage IIB 0 
2.5 1 215 0 0 2 w 58 Stage I 0 
3 1 629 1 0 2 m 53 Stage IIB 1 
2.8 1 329 1 0 3 w 62 Stage IIB 0 
2.8 1 46 0 0 2 w 61 Stage I 0 
2.9 1 406 1 0 3 m 69 Stage IIB 0 
2.1 1 236 0 0 2 w 70 Stage I 1 
2.6 0 2459 0 0 2 w 71 Stage I 
 2.6 
  
1 0 2 m 64 Stage IIB 0 
2.2 1 862 1 0 2 w 64 Stage IIB 0 
2.3 1 448 1 0 2 m 71 Stage IIB 0 
2.5 0 2302 1 0 2 m 64 Stage IIB 
 3 1 287 1 0 3 w 47 Stage IIB 1 
3 0 305 1 0 3 m 62 Stage IIB 
 1.3 1 945 1 0 3 w 75 Stage IIB 0 
2.2 1 832 1 0 3 w 62 Stage IIB 0 
2.9 1 685 0 0 3 w 59 Stage IIA 
 1.2 
  
1 0 3 m 50 Stage IIB 0 
2 1 
 
1 0 2 m 60 Stage IIB 
 1.3 0 2049 0 0 3 m 63 Stage IIA 0 
2.2 
  
1 0 3 m 66 Stage IIB 0 
2.9 1 1045 1 0 3 w 49 Stage IIB 0 
2.9 0 2104 0 0 2 w 64 Stage I 0 
3 1 1743 1 0 2 m 71 Stage IIB 0 
2.2 
  
1 0 3 w 59 Stage IIB 0 
1.2 0 
 
0 0 3 m 59 Stage IIA 0 
2.9 1 744 1 0 3 w 73 Stage IIB 1 
3 1 740 1 0 3 m 50 Stage IIB 0 
3 1 1258 0 0 3 w 62 Stage IIA 0 
2.5 1 809 1 0 3 w 61 Stage IIB 0 
3 1 167 1 0 3 m 66 Stage IIB 0 
2 1 348 1 0 3 w 59 Stage IIB 1 
2.2 1 911 1 0 3 m 64 Stage IIB 0 
2.5 1 779 0 0 3 w 69 Stage IIA 0 
2.9 1 471 0 0 2 w 76 Stage I 0 
2.3 1 125 1 0 3 m 63 Stage IIB 0 
2.2 0 1427 0 0 3 m 65 Stage IIA 1 
3 1 395 0 0 3 m 60 Stage IIA 0 
1.2 1 
 
1 0 2 w 77 Stage IIB 
 3 1 
 
1 0 3 m 38 Stage IIB 
 2 1 
 
1 0 3 w 76 Stage IIB 1 
3 0 
 
1 0 3 m 63 Stage IIB 1 
3 
  
1 0 3 w 65 Stage IIB 0 
2.6 1 432 0 0 2 w 69 Stage I 0 
2.7 1 805 1 0 3 m 
 
Stage IIB 
 2.2 0 2644 0 0 3 w 62 Stage IIA 
 3 1 496 1 0 3 w 79 Stage IIB 
 2.8 1 198 1 0 3 m 49 Stage IIB 0 
3 1 
 
1 0 3 m 70 Stage IIB 
 3 1 404 1 0 3 m 73 Stage IIB 
 2.8 1 
 
0 0 3 w 77 Stage IIA 
 2 1 902 1 0 3 w 73 Stage IIB 
 2.8 1 112 1 1 3 m 55 Stage IV 0 
3 1 715 1 0 3 m 64 Stage IIB 0 
3 1 209 1 0 3 w 51 Stage IIB 0 
2.8 1 260 1 0 3 m 51 Stage IIB 0 
3 1 353 1 0 3 w 67 Stage IIB 0 
3 0 
 
1 0 3 m 48 Stage IIB 
 1.8 1 611 1 0 3 w 78 Stage IIB 0 
2.9 1 98 1 0 3 w 63 Stage IIB 0 
2.7 1 28 0 0 3 w 74 Stage IIA 1 
2.7 0 2645 1 0 2 m 53 Stage IIB 0 
2 0 
 
0 0 2 w 59 Stage I 0 
3 0 2609 1 0 3 m 69 Stage IIB 0 
2.8 1 
 
1 0 3 m 72 Stage IIB 0 
2.8 1 255 1 0 3 m 74 Stage IIB 0 
3 1 
 
0 0 3 m 78 Stage IIA 0 
2.9 1 184 0 0 4 w 72 Stage III 0 
3 1 291 1 0 3 w 69 Stage IIB 0 
3 0 1273 0 0 3 m 56 Stage IIA 0 
3 1 1183 0 0 3 m 50 Stage IIA 0 
2.6 1 96 1 0 3 w 75 Stage IIB 1 
3 1 
 
1 0 3 m 57 Stage IIB 0 
0.7 1 
 
1 0 4 w 70 Stage III 0 
3 1 1064 1 0 3 m 72 Stage IIB 1 
2 1 288 1 0 3 w 61 Stage IIB 0 
2.8 1 192 1 0 4 m 57 Stage III 1 
2.8 1 370 1 0 3 w 74 Stage IIB 0 
2.9 1 1186 1 0 3 w 72 Stage IIB 0 
3 1 394 0 0 3 m 69 Stage IIA 1 
3 0 17 1 0 3 w 68 Stage IIB 1 
1 1 369 0 0 3 w 79 Stage IIA 1 
2.8 
  
1 0 3 w 62 Stage IIB 1 
2.8 0 7 1 0 3 m 60 Stage IIB 1 
3 1 59 1 0 3 w 61 Stage IIB 1 
3 1 289 1 0 4 m 60 Stage III 1 
3 
  
1 0 3 m 70 Stage IIB 0 
2.2 
  
0 0 1 m 66 Stage I 0 
3 1 222 1 0 3 m 61 Stage IIB 1 
2.05 0 415 0 0 3 w 81 Stage IIA 0 
3 1 653 1 1 3 w 46 Stage IV 0 
2 1 12 1 0 4 m 69 Stage III 1 
3 
  
1 0 3 m 59 Stage IIB 1 
2.8 0 12 1 0 3 m 67 Stage IIB 0 
2.8 1 205 1 0 3 m 69 Stage IIB 1 
3 
  
1 0 4 m 73 Stage III 0 
2.5 1 615 1 0 3 m 54 Stage IIB 1 
2.3 1 263 1 0 3 m 67 Stage IIB 1 
2.7 
  
0 0 3 m 65 Stage IIA 0 
2 1 915 0 0 3 m 68 Stage IIA 0 
3 
  
1 0 3 m 75 Stage IIB 0 
2 1 316 1 0 3 m 64 Stage IIB 0 
3 1 
 
1 0 2 m 73 Stage IIB 0 
1.8 0 1079 1 0 3 w 59 Stage IIB 0 
3 1 455 1 0 3 m 56 Stage IIB 0 
2.7 0 210 1 0 3 m 43 Stage IIB 1 
1.2 1 603 1 0 3 w 58 Stage IIB 1 
2.8 0 865 1 0 3 w 57 Stage IIB 0 
2.3 
  
1 0 3 m 77 Stage IIB 1 
3 0 311 1 0 3 m 61 Stage IIB 0 
2.3 1 199 1 1 3 m 41 Stage IV 0 
2.9 0 866 0 0 3 m 75 Stage IIA 0 
2.2 1 582 1 0 3 m 75 Stage IIB 0 
2.1 
  
1 0 3 w 75 Stage IIB 1 
2.3 1 265 1 0 4 m 74 Stage III 1 
2 0 696 1 0 3 w 66 Stage IIB 0 
2.2 1 185 1 0 3 m 51 Stage IIB 1 
2.1 1 268 1 0 3 w 81 Stage IIB 0 
2.9 0 586 0 0 3 m 69 Stage IIA 0 
1.5 0 5 0 0 3 w 69 Stage IIA 0 
2.2 1 1104 1 0 3 w 68 Stage IIB 0 
2.6 1 324 1 0 3 w 68 Stage IIB 1 
2.2 1 380 1 0 3 m 58 Stage IIB 0 
2.3 1 249 1 0 3 w 63 Stage IIB 0 
2.3 1 166 1 0 3 m 72 Stage IIB 0 
2.8 1 216 1 0 3 m 55 Stage IIB 1 
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